doc_id	sent_index	relation_id	relation	trigger	trigger_offset	arg_num	arg_base_np	arg_protein	arg_domain	arg_site	arg_sugar	PSource	SiteSource	NProtein	NID	SiteName	sent_text
30248961	4	15	gly	CF1	681:683	arg1	the monosaccharide compositions	CF1			the monosaccharide compositions	OGER		CF1			HPLC with PMP derivatization analysis indicated that the monosaccharide compositions of CF1 were mannose, glucuronic acid, galacturonic acid, xylose, galactose, arabinose, and trehalose, in a molar ratio of 0.68:0.59:0.27:0.24:0.22:0.67:0.08.
30248961	4	15	gly	CF1	681:683	arg1	mannose	CF1			mannose	OGER		CF1			HPLC with PMP derivatization analysis indicated that the monosaccharide compositions of CF1 were mannose, glucuronic acid, galacturonic acid, xylose, galactose, arabinose, and trehalose, in a molar ratio of 0.68:0.59:0.27:0.24:0.22:0.67:0.08.
29884769	7	82	gly	glycosylate	1244:1254	arg1	its LTA	its LTA				OGER		LTA	P01374		In contrast, the latter strain could glycosylate its LTA at the glycerol O-2 position, which was not observed in the other two strains.
32110292	3	87	gly	N-Glycosylation	433:447	arg1	IgG	IgG				Cterm		IgG			N-Glycosylation of IgG is crucial for its effector function and makes IgG highly heterogeneous both in structure and function, although all four subclasses of IgG contain only a single N-glycosylation site in the Fc region with a highly similar amino acid sequence.
30669833	0	62	gly	Signatures	96:105	arg1	PSA	PSA			Signatures	PUBTATOR		PSA	354		Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
31289257	7	45	gly	hyperglycosylation	1320:1337	arg1	MAP6	MAP6				PUBTATOR		MAP6	17760		This is the first study to described MAP6 as a glycoprotein containing Gal-(β-1,3)-GalNAc oligosaccharides and to show that hyperglycosylation of MAP6 is strongly associated with the pathogenesis of PD.
31289257	7	59	gly	glycoprotein	1243:1254	arg1	MAP6	MAP6				PUBTATOR		MAP6	17760		This is the first study to described MAP6 as a glycoprotein containing Gal-(β-1,3)-GalNAc oligosaccharides and to show that hyperglycosylation of MAP6 is strongly associated with the pathogenesis of PD.
29579062	11	46	gly	glycoprotein	2134:2145	arg1	the virus Env glycoprotein	the virus Env glycoprotein				PUBTATOR		Env glycoprotein	155971		Overall, our data demonstrate that HIV-1 isolates display differential sensitivity to lectins, in part due to the microheterogeneity of N-linked glycans expressed on the surface of the virus Env glycoprotein.
31244828	1	64	gly	glycoprotein	172:183	arg1	MOG	MOG				PUBTATOR		MOG	4340		Autoantibodies to myelin oligodendrocytes glycoprotein (MOG) are found in a fraction of patients with inflammatory demyelination and are detected with MOG-transfected cells.
31489526	1	17	gly	glycosylated	109:120	arg1	Alpha-2-macroglobulin	Alpha-2-macroglobulin				OGER		Alpha-2-macroglobulin	P01023		Alpha-2-macroglobulin (A2M) is a glycosylated broad spectrum inhibitor of numerous proteases, including those involved in blood coagulation.
29346724	8	42	gly	has	982:984	arg1	EXTL3ΔN AND N-glycans	EXTL3ΔN			N-glycans	PUBTATOR		EXTL3ΔN	2137		Our data show that EXTL3ΔN has N-glycans at least at two positions, Asn290 and Asn592, which seem to be critical for proper protein folding and/or release.
31411531	8	67	gly	glycan	1540:1545	arg1	human-derived IgG	IgG			glycan	Cterm		IgG			The alpha 2,6-linked sialic acid on the 3-arm (the major sialylated glycan in human-derived IgG), and the alpha 2,3-linked sialic acid on the 3-arm, do not have this destabilizing effect.
29339133	5	7	gly	antithrombin	646:657	arg1	The disaccharide compositions	antithrombin III			The disaccharide compositions	PUBTATOR		antithrombin III	462		The disaccharide compositions, 3-O-sulfo group-containing tetrasaccharides composition, and antithrombin III-binding affinity of the fractions from this LMWH were analyzed.
29339133	5	11	gly	III-binding	659:669	arg1	The disaccharide compositions	antithrombin III			The disaccharide compositions	PUBTATOR		antithrombin III	462		The disaccharide compositions, 3-O-sulfo group-containing tetrasaccharides composition, and antithrombin III-binding affinity of the fractions from this LMWH were analyzed.
30111774	5	34	gly	O-glycosylated	778:791	arg1	MUC1	MUC1				OGER		MUC1	P15941		Moreover, immunoblotting assays demonstrated reactivity to tumour-associated O-glycosylated proteins, such as MUC1.
29343515	7	11	gly	glycosylated	1134:1145	arg1	LTA	LTA				OGER		LTA	P01374		LTA is polymerized on the outside of the cell and hence can only be glycosylated extracellularly.
30624066	1	2	gly	glycoproteins	277:289	arg1	GPs	GPs				OGER		GPs			A multipronged electrospray ionization mass spectrometry (ESI-MS) approach for investigating glycan-mediated interactions between water-soluble glycan-binding proteins (GBPs) and glycoproteins (GPs) is described.
31025190	0	46	gly	glycosylation	37:49	arg1	human interferon-gamma	human interferon-gamma				PUBTATOR		interferon-gamma	3458		Molecular modeling of the effects of glycosylation on the structure and dynamics of human interferon-gamma.
29767770	6	76	gly	de-O-glycosylated	1078:1094	arg1	de-O-glycosylated PGM	de-O-glycosylated PGM				OGER		PGM	P13611		In addition, de-O-glycosylated PGM was not able to inhibit F. oxysporum phagocytosis, suggesting that macrophages recognize and internalize F. oxysporum via PGM.
29408873	5	72	gly	glycoform	1168:1176	arg1	the truncated mIgG2c Fc glycoform	the truncated mIgG2c Fc glycoform				Cterm		IgG2c			Secondary structural elements surrounding the Asn297 site of glycosylation form longer beta strands in the truncated mIgG2c Fc glycoform when compared to mIgG2c with the complex-type N-glycan.
29408873	5	72	gly	glycoform	1168:1176	arg1	the truncated mIgG2c Fc glycoform	the truncated mIgG2c Fc glycoform				Cterm		Fc			Secondary structural elements surrounding the Asn297 site of glycosylation form longer beta strands in the truncated mIgG2c Fc glycoform when compared to mIgG2c with the complex-type N-glycan.
30651366	14	129	gly	types	2594:2598	arg1	insect cell E2	E2			types	Cterm		E2			Mass spectrometry demonstrated that the predicted glycosylation sites were utilized in both mammalian and insect cell E2, although the glycan types in insect cell E2 were smaller and less complex.
31040211	2	43	gly	E2	397:398	arg1	N-linked glycans	E2			N-linked glycans	Cterm		E2			However, this effort has proven challenging because HCV evades neutralizing antibodies (NAbs) through molecular features of viral envelope glycoprotein E2, including hypervariable region 1 (HVR1) and N-linked glycans.
30361439	11	32	part_of	Asp-129	1620:1626	arg1	CD16b	CD16b		Asp-129		PUBTATOR	SpecificSite	CD16b	O75015	Asp-129	These results reveal how Asp-129 in CD16b affects its binding affinity for IgG1 Fc and suggest that antibodies engineered to engage CD16b with high affinity must accommodate the Asp-129 side chain.
30612270	6	54	gly	glycosylation	990:1002	arg1	human serum ceruloplasmin	human serum ceruloplasmin				PUBTATOR		ceruloplasmin	1356		The four glycosylation sites of human serum ceruloplasmin from 17 different individuals were analyzed using glycopeptides of varying peptide lengths, obtained by action of different proteases and by limited digestion.
29885470	7	37	gly	derived	1107:1113	arg1	FBS AND The Fmoc-derivatized N-glycans	FBS			The Fmoc-derivatized N-glycans	OGER		FBS			The Fmoc-derivatized N-glycans derived from chicken ovalbumin, Fagopyrum esculentum Moench Pollen and FBS were successfully analyzed by online LC/MS to distinguish isomers.
30641224	6	0	gly	present	1070:1076	arg1	HDL AND N-glycans	HDL			N-glycans	OGER		HDL	Q9UNE0		The majority of N-glycans present in HDL (~70%) and LDL (~60%) were sialylated with one or two sialic acid residues.
31173827	2	43	gly	FMS	345:347	arg1	the carbohydrate composition	FMS			the carbohydrate composition	OGER		FMS	P07333		The variation in the carbohydrate composition of FMS was analysed when subjected to different pretreatments.
29443078	4	49	gly	2,6-di-sialylated	966:982	arg1	SCT	SCT				OGER		SCT	P09683		In particular, the binding behavior of a newly isolated HIV-1 broadly neutralizing antibody (bNAb), PG9, to the mixture of closely spaced Man5GlcNAc2 (Man5) and 2,6-di-sialylated bi-antennary complex type N-glycan (SCT) on an ACG array, opens a new avenue to guide the effective immunogen design for HIV vaccine development.
29437979	14	65	gly	glycoproteins	2172:2184	arg1	gH	gH				PUBTATOR		gH	8836		Viral envelope glycoproteins, such as gH, usually contain N-glycans, which can have a strong impact on their folding, transport, and functions.
29437979	14	68	gly	contain	2207:2213	arg1	gH AND N-glycans	gH			N-glycans	PUBTATOR		gH	8836		Viral envelope glycoproteins, such as gH, usually contain N-glycans, which can have a strong impact on their folding, transport, and functions.
30397756	0	71	gly	glycosylation	28:40	arg1	fibrinogen	fibrinogen				PUBTATOR		fibrinogen	2244		Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma-correlation with liver cancer and liver cirrhosis.
29596681	5	19	gly	N-glycans	943:951	arg1	human IgG1	IgG1			N-glycans	OGER		IgG1	P01857		We previously explored precise gene engineering and design options for N-glycosylation in CHO cells, and here we focus on engineering options possible for N-glycans on human IgG1.
30892132	2	69	gly	glycosylation	395:407	arg1	PD-1	PD-1				PUBTATOR		PD-1	5133		However, the structural basis of the binding mechanisms of the mAbs and PD-1 and the effects of glycosylation of PD-1 on mAb interaction are not well understood.
31111416	2	7	gly	glycosylation	326:338	arg1	Env	Env				PUBTATOR		Env	100616444		A comprehensive LC-MS/MS peptide mapping analysis was applied to assess the primary sequence, glycosylation profiles, and glycosite occupancy of Env to ensure the adequate mimicking of the native immunogen.
31021647	1	2	gly	A	159:159	arg1	the hexasaccharide fragment	landomycin A			the hexasaccharide fragment	Cterm		landomycin A			The synthesis of the hexasaccharide fragment of landomycin A is reported.
30714583	3	14	gly	IgG	391:393	arg1	terminal galactosylated N-glycans	IgG			terminal galactosylated N-glycans	Cterm		IgG			A decrease in terminal galactosylated N-glycans of serum IgG in rheumatoid arthritis (RA) and osteoarthritis (OA) may be involved in their immunopathogenesis.
31084922	2	1	gly	O-glycosylated	296:309	arg1	Serum IgA1	Serum IgA1				PUBTATOR		Serum IgA1	P01876		Serum IgA1 is abnormally O-glycosylated in IgA nephropathy, which may contribute to the development of glomerular injury.
30908021	3	59	gly	neuraminidase	620:632	arg1	the N-glycans	neuraminidase			the N-glycans	PUBTATOR		neuraminidase	4758		Using liquid chromatography-mass spectrometry, we have analyzed the N-glycans of influenza viral hemagglutinin and neuraminidase from several subtypes of influenza vaccines, and utilized the existing resource to establish an N-glycan library consisting of 927 N-glycan structures and 387 sulfated N-glycan compositions.
31884067	9	57	gly	glycoproteins	1316:1328	arg1	neural cell adhesion molecule	neural cell adhesion molecule				PUBTATOR		neural cell adhesion molecule	4684		We also showed that the expression of HNK-1 carrier glycoproteins such as neural cell adhesion molecule (NCAM), L1 and AMPA receptor subunit GluA2 were also increased in the PRMT1-deficient cerebellum.
31884067	9	57	gly	glycoproteins	1316:1328	arg1	AMPA receptor subunit	L1 and AMPA receptor subunit				PUBTATOR		L1 and AMPA receptor subunit	3897		We also showed that the expression of HNK-1 carrier glycoproteins such as neural cell adhesion molecule (NCAM), L1 and AMPA receptor subunit GluA2 were also increased in the PRMT1-deficient cerebellum.
29615747	7	37	gly	N-glycans	1093:1101	arg1	GPs	GPs			N-glycans	OGER		GPs			Therefore, these data strongly suggest that extended N-glycans on GPs reduce MGL/CD301-mediated viral infectivity by hindering the interaction between GPs and MGL/CD301 preferentially binds O-glycans.
31601857	0	39	gly	glycoprotein	20:31	arg1	Fucosylated α1-acid glycoprotein	Fucosylated α1-acid glycoprotein				Cterm		α1-acid			Fucosylated α1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer.
31021647	0	15	gly	A	55:55	arg1	the Hexasaccharide Fragment	Landomycin A Using			the Hexasaccharide Fragment	Cterm		Landomycin A Using			Synthesis of the Hexasaccharide Fragment of Landomycin A Using a Mild, Reagent-Controlled Approach.
29709182	1	27	gly	-β-d-Gal	255:262	arg1	a branched heptasaccharide α-Neu p5Ac-(2→3)-β-d-Gal p-(1→4)-β-d-GlcN pAc-(1→3)-{[β-d-Gal p-(1→6)]-β-d-Gal p}-(1→4)-β-d-Glc p-(1→3)-β-d-Glc p-(1→	Gal			a branched heptasaccharide α-Neu p5Ac-(2→3)-β-d-Gal p-(1→4)-β-d-GlcN pAc-(1→3)-{[β-d-Gal p-(1→6)]-β-d-Gal p}-(1→4)-β-d-Glc p-(1→3)-β-d-Glc p-(1→	OGER		Gal	P22466		The first chemical synthesis of the repeating unit of serotype II group B Streptococcus capsular polysaccharide, a branched heptasaccharide α-Neu p5Ac-(2→3)-β-d-Gal p-(1→4)-β-d-GlcN pAc-(1→3)-{[β-d-Gal p-(1→6)]-β-d-Gal p}-(1→4)-β-d-Glc p-(1→3)-β-d-Glc p-(1→, was achieved by convergent [4+2+1] glycosylation, after probing different synthetic strategies and overcoming a series of difficulties.
29709182	1	63	gly	α-Neu	239:243	arg1	a branched heptasaccharide α-Neu p5Ac-(2→3)-β-d-Gal p-(1→4)-β-d-GlcN pAc-(1→3)-{[β-d-Gal p-(1→6)]-β-d-Gal p}-(1→4)-β-d-Glc p-(1→3)-β-d-Glc p-(1→	Neu			a branched heptasaccharide α-Neu p5Ac-(2→3)-β-d-Gal p-(1→4)-β-d-GlcN pAc-(1→3)-{[β-d-Gal p-(1→6)]-β-d-Gal p}-(1→4)-β-d-Glc p-(1→3)-β-d-Glc p-(1→	OGER		Neu	P04626		The first chemical synthesis of the repeating unit of serotype II group B Streptococcus capsular polysaccharide, a branched heptasaccharide α-Neu p5Ac-(2→3)-β-d-Gal p-(1→4)-β-d-GlcN pAc-(1→3)-{[β-d-Gal p-(1→6)]-β-d-Gal p}-(1→4)-β-d-Glc p-(1→3)-β-d-Glc p-(1→, was achieved by convergent [4+2+1] glycosylation, after probing different synthetic strategies and overcoming a series of difficulties.
30641224	9	57	gly	desialylated	1563:1574	arg1	desialylated HDL	desialylated HDL				OGER		HDL	Q9UNE0		Native HDL displayed significantly greater efficacy in removing cellular cholesterol from THP-1 cells as compared to desialylated HDL (p < 0.05).
30403372	0	28	gly	glycosylated	86:97	arg1	a glycosylated HIV-1 gp120	a glycosylated HIV-1 gp120				PUBTATOR		HIV-1 gp120	155971		Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.
31423004	1	10	gly	oligosaccharide	303:317	arg1	Asn135			Asn135	Asn135		AminoAcid			Asn135	Human antithrombin (AT) has two isoforms of which the predominant α-form is glycosylated on all four possible glycosylation sites and the lower abundant β-isoform lacks the oligosaccharide on Asn135.
31423004	2	36	gly	AT	374:375	arg1	The main oligosaccharide structure	AT			The main oligosaccharide structure	Cterm		AT	462		The main oligosaccharide structure of human AT consists of biantennary complex-type oligosaccharides lacking a core fucose.
31411531	3	44	gly	have	527:530	arg1	Recombinant IgGs AND sialic acids	Recombinant IgGs			sialic acids	Cterm		Recombinant IgGs			Recombinant IgGs expressed in Chinese hamster ovary (CHO) cells, however, have sialic acids through alpha 2,3-linkages because of the lack of the alpha 2,6-sialyltransferase gene.
31084922	3	70	gly	O-glycosylated	402:415	arg1	Abnormal O-glycosylated IgA1	Abnormal O-glycosylated IgA1				PUBTATOR		IgA1	P01876		Abnormal O-glycosylated IgA1 was also detected in HSPN using lectin enzyme-linked immunosorbent assay; however, this method cannot provide the exact structural information of O-glycans.
30935958	9	33	gly	N-glycosylated	1111:1124	arg1	In vivo PrP	In vivo PrP				PUBTATOR		PrP	5621		In vivo PrP is N-glycosylated at positions Asn181 and Asn197.
29638186	5	50	gly	mucin	880:884	arg1	mucin O-glycans	mucin			mucin O-glycans	PUBTATOR		mucin	100508689		Mass spectrometric analysis of mucin O-glycans from the porcine mucin showed that individual variation in binding is reflected by a difference in glycosylation; of 109 oligosaccharide structures identified, only 14 were present in all examined samples.
30030954	5	38	gly	deglycosylated	1005:1018	arg1	fully deglycosylated lactoferrin	fully deglycosylated lactoferrin				OGER		lactoferrin	P02788		The results showed that native and sialylated glycans enriched lactoferrin have similar minimum inhibitory concentration (MIC) values against E.coli DH5a (1 mg/ml), whereas the MIC value for fully deglycosylated lactoferrin was 6mg/ml.
31554601	5	56	gly	mIgG1s	705:710	arg1	different N-glycan patterns	IgG1s			different N-glycan patterns	Cterm		IgG1s	16017		Here, we generated mIgG1s with different N-glycan patterns by adding different types of N-glycan processing enzyme inhibitors to the hybridoma culture media, before comparing their FcγR-binding affinity using enzyme-linked immunosorbent assay (ELISA) analysis.
30134158	0	46	gly	Glycosylation	14:26	arg1	Virion-Derived HIV-1 Env	Virion-Derived HIV-1 Env				PUBTATOR		Env	155971		Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.
30674035	3	40	gly	IgG	452:454	arg1	N-glycans	IgG			N-glycans	Cterm		IgG			Here, we characterized N-glycans of CSF IgG from ALS patients in comparison with a control group of other neurological diseases.
31190665	2	51	gly	glycosylated	463:474	arg1	a σ class glycosylated GST	a σ class glycosylated GST				OGER		GST			Here we have identified and characterized a σ class glycosylated GST (OoGST1), from the cattle-infective filarial nematode Onchocerca ochengi, which is homologous (99% amino acid identity) with an immunodominant GST and potential vaccine candidate from the human parasite, O. volvulus, (OvGST1b).
29411222	7	22	gly	glycans	1247:1253	arg1	N171			N171	N171		SpecificSite			N149 and N171	N-Glycopeptide analysis with UHPLC-QTOF-MSE confirmed the N-glycosylation sites (N149, N171 and N317) as well as Fc-specific glycosylation on N317, and TNFR-specific highly sialylated glycans on N149 and N171 on both investigated products.
29411222	7	22	gly	glycans	1247:1253	arg1	N149			N149	N149		SpecificSite			N149 and N171	N-Glycopeptide analysis with UHPLC-QTOF-MSE confirmed the N-glycosylation sites (N149, N171 and N317) as well as Fc-specific glycosylation on N317, and TNFR-specific highly sialylated glycans on N149 and N171 on both investigated products.
31669606	8	22	gly	fucosylated	1229:1239	arg1	fucosylated IgG1	fucosylated IgG1				OGER		IgG1	P01857		The affinities measured for the HM and Man5 IgG4-Fc (0.39-0.52 μM) are similar to those measured for fucosylated IgG1.
30963354	5	85	gly	polysaccharides	631:645	arg1	ECM	ECM			polysaccharides	OGER		ECM	Q13201		GAGs are anionic polysaccharides in extracellular matrix (ECM) that have been implicated in limb and lens regeneration of amphibians, however, GAGs have not been investigated in the context of retinal regeneration.
29408166	3	13	gly	core-fucosylated	654:669	arg1	PSA	PSA				PUBTATOR		PSA	354		Here, we present a mass spectrometry-based strategy for the simultaneous analysis of core-fucosylated and total prostate-specific antigen (PSA) in human serum in the low ng/ml concentration range.
29408166	3	13	gly	core-fucosylated	654:669	arg1	core-fucosylated and total prostate-specific antigen	core-fucosylated and total prostate-specific antigen				PUBTATOR		prostate-specific antigen	354		Here, we present a mass spectrometry-based strategy for the simultaneous analysis of core-fucosylated and total prostate-specific antigen (PSA) in human serum in the low ng/ml concentration range.
31592495	8	0	gly	glycans	1221:1227	arg1	residues N311 and N333			residues N311 and N333	residues N311 and N333		SpecificSite			residues N311 and N333	Biochemically, tumor-associated CD73 was deficient in hybrid and complex glycans specifically on residues N311 and N333 located in the C-terminal catalytic domain.
31592495	8	0	gly	glycans	1221:1227	arg1	N333			N333	N333		SpecificSite			residues N311 and N333	Biochemically, tumor-associated CD73 was deficient in hybrid and complex glycans specifically on residues N311 and N333 located in the C-terminal catalytic domain.
31494931	7	4	gly	N-glycosylation	772:786	arg1	Glut1	Glut1				PUBTATOR		Glut1	6513		Furthermore, MGAT1 promotes complex N-glycosylation of glucose transporter 1 (Glut1) and increases Glut1 protein levels.
29888865	12	29	gly	glycosylation	1851:1863	arg1	rFVIII	rFVIII				PUBTATOR		FVIII	2157		Although site-specific glycosylation of rFVIII proved consistent with pdFVIII regardless of the expression system, the entire N-glycan content of each sample appeared significantly different.
30669833	2	36	gly	glycoforms	490:499	arg1	PSA glycoforms	PSA glycoforms				PUBTATOR		PSA	354		In order to improve the specificity and exclude a false positive diagnosis in PSA test, PCa-specific glycosylation subtypes of PSA were explored using in-depth quantitative profiling of PSA glycoforms based on mass spectrometric oxonium ion monitoring technology.
30578591	2	49	gly	glycosylation	224:236	arg1	NA	NA				Cterm		NA	4758		The glycosylation of neuraminidase (NA) could affect the infectivity and virulence of the influenza virus, but detailed site-specific glycosylation information of NA is still missing.
30578591	2	49	gly	glycosylation	224:236	arg1	neuraminidase	neuraminidase				PUBTATOR		neuraminidase	4758		The glycosylation of neuraminidase (NA) could affect the infectivity and virulence of the influenza virus, but detailed site-specific glycosylation information of NA is still missing.
30030954	0	36	gly	deglycosylation	10:24	arg1	lactoferrin	lactoferrin				OGER		lactoferrin	P02788		Selective deglycosylation of lactoferrin to understand glycans' contribution to antimicrobial activity of lactoferrin.
30134158	1	13	gly	glycoprotein	243:254	arg1	envelope glycoprotein	envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes.
30134158	1	13	gly	glycoprotein	243:254	arg1	Env	Env				PUBTATOR		Env	155971		Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes.
29593217	3	14	gly	glycosylated	561:572	arg1	natively glycosylated Env trimers	natively glycosylated Env trimers				PUBTATOR		Env trimers	100616444		Here we present crystal structures, including a 3.8-Å X-ray free electron laser dataset, of natively glycosylated Env trimers complexed with BG18, the most potent V3/N332gp120 glycan-targeting bNAb reported to date.
31558607	2	10	part_of	carries	380:386	arg1	ProBDNF AND Asn-127	ProBDNF		Asn-127		PUBTATOR	SpecificSite	ProBDNF	627	Asn-127	ProBDNF carries a single N-glycosylation sequon (Asn-127) that remains virtually unstudied despite being located in a highly conserved region proximal to the proteolytic site.
29642453	3	59	gly	glycosylation	439:451	arg1	NA	NA				Cterm		NA	4758		We monitored the potential N-linked glycosylation (NLG) sites of over 10,000 HA and NA of H1N1 subtype isolated from human, avian, and swine species over the past century.
29888865	9	70	gly	N-glycosylation	1318:1332	arg1	human plasma-derived (pd)FVIII	human plasma-derived (pd)FVIII				PUBTATOR		FVIII	2157		Seeking to better understand the glycosylation mechanisms underlying FVIII biology, we studied the N-glycosylation of human plasma-derived (pd)FVIII and six rFVIII products expressed in CHO, BHK or HEK cell lines.
29751008	8	9	gly	glycoforms	1595:1604	arg1	various IgG glycoforms	various IgG glycoforms				Cterm		IgG			These well-defined IgG1-Fc glycoforms serve as a useful model system to identify physicochemical stability and local backbone flexibility data sets potentially discriminating between various IgG glycoforms for potential applicability to future comparability or biosimilarity assessments.
29751008	8	59	gly	glycoforms	1427:1436	arg1	These well-defined IgG1-Fc glycoforms	These well-defined IgG1-Fc glycoforms				OGER		IgG1	P01857		These well-defined IgG1-Fc glycoforms serve as a useful model system to identify physicochemical stability and local backbone flexibility data sets potentially discriminating between various IgG glycoforms for potential applicability to future comparability or biosimilarity assessments.
30669833	7	88	gly	glycoforms	1319:1328	arg1	both PSA glycoforms	both PSA glycoforms				PUBTATOR		PSA	354		Moreover, both PSA glycoforms showed significant correlation with Gleason scores.
31111416	1	42	gly	glycoprotein	125:136	arg1	HIV Env glycoprotein	HIV Env glycoprotein				PUBTATOR		HIV Env glycoprotein	100616444		Characterization of HIV Env glycoprotein with 28 glycosylation sites is the essential step of structure-based vaccine design programs.
31409668	4	5	gly	N-glycosylation	636:650	arg1	SIgA	SIgA				Cterm		IgA			In this work, we performed a glycomic study to compare N-glycosylation of SIgA purified from mature breast milk and saliva, and plasma IgA from the same lactating participants.
31174130	6	0	gly	IgG	986:988	arg1	The released and derivatized N-glycans	IgG			The released and derivatized N-glycans	Cterm		IgG			The released and derivatized N-glycans of human plasma, IgG and human transferrin were successfully purified by titania glyco-purification tips for the analysis by MALDI-MS.
31174130	6	54	gly	transferrin	1000:1010	arg1	The released and derivatized N-glycans	transferrin			The released and derivatized N-glycans	PUBTATOR		transferrin	7018		The released and derivatized N-glycans of human plasma, IgG and human transferrin were successfully purified by titania glyco-purification tips for the analysis by MALDI-MS.
29340583	9	58	gly	glycosylated	1697:1708	arg1	glycosylated HgpA	glycosylated HgpA				OGER		HgpA	P02724		Glycopeptide purification by zwitterionic-hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry identified six glycosites from five H. pullorum proteins, which was consistent with proteins reactive with a polyclonal antiserum generated against glycosylated HgpA.
30335821	3	15	gly	glycoprotein	770:781	arg1	HIV envelope glycoprotein	HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	155971		We find that diverse forms of HIV envelope glycoprotein can be efficiently expressed at the yeast cell surface and that gp140 forms of Env are effectively cleaved by Kex2p, the yeast furin protease homolog.
31851597	4	41	gly	glycosylation	831:843	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		Using genetically engineered cells lacking all four TMTC genes, overexpression of TMTC3 rescued O-linked glycosylation of E-cadherin and cell adherence.
30641224	7	18	gly	structure	1188:1196	arg1	HDL	HDL			structure	OGER		HDL	Q9UNE0		The most abundant N-glycan structure in both HDL and LDL was a complex type biantennary N-glycan with one sialic acid (A2G2S1).
29769321	7	60	part_of	RpNCRD	1390:1395	arg1	Asn-303	RpNCRD		Asn-303		Cterm	SpecificSite	RpNCRD	6441	Asn-303	MS analysis revealed an N-glycan site-occupancy of >98% at Asn-303 of RpNCRD with complex-type, heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides.
29858715	6	40	gly	carries	734:740	arg1	PIP AND unusual highly fucosylated N-linked glycans	PIP			unusual highly fucosylated N-linked glycans	PUBTATOR		PIP	5304		PIP carries unusual highly fucosylated N-linked glycans with multiple Lewisy (Ley) epitopes on bi-, tri- and tetraantennary structures resulting in up to nine fucosyl residues on a tetraantennary glycan.
29888865	11	40	gly	found	1810:1814	arg2	pdFVIII AND NeuGc	pdFVIII			NeuGc	PUBTATOR		FVIII	2157		Results/Conclusion The results of our study detail the N-glycan repertoire of pdFVIII to an unprecedented level, and for the first time, provide evidence of N-glycolylneuraminic acid (NeuGc) found on pdFVIII.
29888865	11	40	gly	found	1810:1814	arg2	pdFVIII AND N-glycolylneuraminic acid	pdFVIII			N-glycolylneuraminic acid	PUBTATOR		FVIII	2157		Results/Conclusion The results of our study detail the N-glycan repertoire of pdFVIII to an unprecedented level, and for the first time, provide evidence of N-glycolylneuraminic acid (NeuGc) found on pdFVIII.
29858715	0	83	gly	glycosylation	15:27	arg1	PIP	PIP				PUBTATOR		PIP	5304		Unusual N-type glycosylation of salivary prolactin-inducible protein (PIP): multiple LewisY epitopes generate highly-fucosylated glycan structures.
29858715	0	83	gly	glycosylation	15:27	arg1	salivary prolactin-inducible protein	salivary prolactin-inducible protein				PUBTATOR		prolactin-inducible protein	5304		Unusual N-type glycosylation of salivary prolactin-inducible protein (PIP): multiple LewisY epitopes generate highly-fucosylated glycan structures.
30553446	8	0	gly	IgA	1008:1010	arg1	the IgA1 O-glycan structure	IgA			the IgA1 O-glycan structure	PUBTATOR		IgA	973		Next, we evaluated the IgA1 O-glycan structure of serum IgA from IgAN recipients (n = 26), IgAD donors (n = 17), and non-IgAD helthy donors (n = 27) using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).
30361439	10	72	gly	glycosylated	1394:1405	arg1	glycosylated CD16b	glycosylated CD16b				PUBTATOR		CD16b	O75015		A model of glycosylated CD16b bound to IgG1 Fc determined to 2.2 Å resolution combined with a 250-ns all-atom molecular dynamics simulation showed that the larger Asp-129 residue deformed the Fc-binding surface.
31851597	0	69	gly	E-cadherin	84:93	arg1	O-mannosylation	E-cadherin			O-mannosylation	PUBTATOR		E-cadherin	999		Endoplasmic reticulum transmembrane protein TMTC3 contributes to O-mannosylation of E-cadherin, cellular adherence, and embryonic gastrulation.
31851597	0	77	gly	O-mannosylation	65:79	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		Endoplasmic reticulum transmembrane protein TMTC3 contributes to O-mannosylation of E-cadherin, cellular adherence, and embryonic gastrulation.
30111543	3	50	gly	microheterogeneity	519:536	arg1	haptoglobin	haptoglobin				OGER		haptoglobin	P00738		Here, we apply mass spectrometry-based approaches to elucidate the global and site-specific microheterogeneity of two plasma proteins: α1-acid glycoprotein (AGP) and haptoglobin (Hp).
30959857	3	58	gly	hips	493:496	arg1	polysaccharide-rich extracts	hips			polysaccharide-rich extracts	OGER		hips	Q9NPH2		The content and biological activity of polysaccharides in rose organs is an almost completely unaddressed topic, therefore, polysaccharide-rich extracts (crude polysaccharides, CPLs) from petals, leaves, hips, and achenes of Rosa rugosa Thunb.
29642453	0	48	gly	Glycosylation	0:12	arg1	Neuraminidase	Neuraminidase				PUBTATOR		Neuraminidase	4758		Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs.
29858715	5	14	gly	glycosylation	649:661	arg1	PIP	PIP				PUBTATOR		PIP	5304		We found a very uncommon N-type glycosylation of PIP in healthy individuals from both, seminal fluid and saliva.
29587225	1	7	gly	glycoprotein	186:197	arg1	Recombinant human erythropoietin	Recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Recombinant human erythropoietin (EPO) is a therapeutic glycoprotein widely used for treating anemia.
30908644	1	19	gly	isolated	187:194	arg1	PSP AND Four polysaccharide fractions	PSP			Four polysaccharide fractions	OGER		PSP	O60542		Four polysaccharide fractions (P-1: 71.40%, P-2: 1.95%, P-3: 1.14%, P-4: 1.64%) were isolated from crude Polygonatum sibiricum polysaccharide (PSP), processed by water extraction, ethanol precipitation, and further separated with diethylaminoethyl cellulose-52 anion-exchange chromatography.
29330305	6	24	gly	CD16a	1370:1374	arg1	oligomannose N-glycans	CD16a			oligomannose N-glycans	PUBTATOR		CD16a	2214		Of note, these differences in CD16a N-glycan composition affected antibody binding: CD16a with oligomannose N-glycans bound IgG1 Fc with 12-fold greater affinity than did CD16a having primarily complex-type and highly branched N-glycans.
29330305	6	45	gly	having	1463:1468	arg1	CD16a AND primarily complex-type and highly branched N-glycans	CD16a			primarily complex-type and highly branched N-glycans	PUBTATOR		CD16a	2214		Of note, these differences in CD16a N-glycan composition affected antibody binding: CD16a with oligomannose N-glycans bound IgG1 Fc with 12-fold greater affinity than did CD16a having primarily complex-type and highly branched N-glycans.
30759204	12	70	gly	O-glycosylation	1574:1588	arg1	IgA1	IgA1				PUBTATOR		IgA1	P01876		Our data indicated a link between site-specific glycan addition and clustered glycan density that defines a mechanism of how conserved clustered O-glycosylation patterns and glycoform populations of IgA1 can be controlled by GalNAc-T2.
29619832	1	6	gly	glycoprotein	200:211	arg1	Human lysyl oxidase-like 2	Human lysyl oxidase-like 2				PUBTATOR		Human lysyl oxidase-like 2	4017		Human lysyl oxidase-like 2 (hLOXL2), a glycoprotein implicated in tumor progression and organ fibrosis, is a molecular target for anticancer and antifibrosis treatment.
29408166	5	75	gly	core-fucosylated	1174:1189	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		The method was shown to be linear from 0.5 to 60 ng/ml total PSA concentrations and allows the simultaneous quantification of core-fucosylated PSA down to 1 ng/ml and total PSA lower than 0.5 ng/ml.
29324282	5	0	gly	deglycosylated	863:876	arg1	IgG1	IgG1				OGER		IgG1	P01857		Three different glycan-modified forms of IgG1 (fully deglycosylated, hypergalactosylated and hypersialylated) were produced and characterized alongside the unmodified mAb molecule.
29324282	5	49	gly	IgG1	851:854	arg1	Three different glycan-modified forms	IgG1			Three different glycan-modified forms	OGER		IgG1	P01857		Three different glycan-modified forms of IgG1 (fully deglycosylated, hypergalactosylated and hypersialylated) were produced and characterized alongside the unmodified mAb molecule.
30503285	4	18	gly	O-glycosylated	801:814	arg1	the naturally O-glycosylated human interferon α-2b	the naturally O-glycosylated human interferon α-2b				PUBTATOR		interferon α-2b	3440		The effectiveness of this two-plasmid synthetic operon system has been tested on three proteins with therapeutic potential: the native and an engineered version of the naturally O-glycosylated human interferon α-2b, as well as human growth hormone with one engineered site of glycosylation.
29991969	7	19	gly	GlcNAc	1413:1418	arg1	IgG	IgG			GlcNAc	Cterm		IgG			MGAT3 promoter methylation correlated significantly with galactosylation, sialylation, and bisecting GlcNAc on IgG of the same patients, suggesting that activity of the GnT-III enzyme, encoded by this gene, might be altered in IBD.
29991969	7	106	gly	sialylation	1386:1396	arg1	IgG	IgG			sialylation	Cterm		IgG			MGAT3 promoter methylation correlated significantly with galactosylation, sialylation, and bisecting GlcNAc on IgG of the same patients, suggesting that activity of the GnT-III enzyme, encoded by this gene, might be altered in IBD.
30674035	6	18	gly	N-glycosylation	876:890	arg1	ALS CSF IgG	ALS CSF IgG				Cterm		IgG			The N-glycosylation profile of ALS CSF IgG consisted of diantennary N-glycans predominantly with proximal fucose and some bisecting GlcNAc; agalacto-, mono-, and digalactosylated as well as α2,6-sialylated structures were detected.
30842877	5	43	gly	acid	1032:1035	arg1	IgA1	IgA1			acid	PUBTATOR		IgA1	P01876		An increase in Sambucus nigra binding was observed, suggestive of increased α2,6-linked sialic acid on IgA1 in BCa.
30389790	0	93	gly	glycoprotein	37:48	arg1	glucosidase I-mediated glycoprotein deglucosylation	glucosidase I-mediated glycoprotein deglucosylation				PUBTATOR		glucosidase I-mediated glycoprotein	7841		Abrogation of glucosidase I-mediated glycoprotein deglucosylation results in a sick phenotype in fission yeasts: Model for the human MOGS-CDG disorder.
29888865	5	84	gly	glycoprotein	590:601	arg1	Background/Objective Human factor VIII	Background/Objective Human factor VIII				PUBTATOR		Human factor VIII	2157		SUMMARY: Background/Objective Human factor VIII (FVIII) is a plasma glycoprotein, defects of which result in hemophilia A. Current substitution therapy uses FVIII products purified from human plasma or from various cell lines (recombinant FVIII) with different levels of B-domain deletion.
30578591	5	4	gly	has	749:751	arg1	The NA AND more complex glycans	The NA			more complex glycans	Cterm		NA	4758		The NA expressed in human cells has more complex glycans than that of insect cells, suggesting the importance of selecting an appropriate expression system for the production of functional glycoproteins.
31719148	5	19	gly	N-deglycosylation	1001:1017	arg1	CCH	CCH, FLH				PUBTATOR		CCH, FLH	384452		Here, we report that enzyme-catalyzed N-deglycosylation of CCH, FLH, and KLH disrupts their quaternary structure and impairs their immunogenic effects.
29642453	1	58	gly	Glycosylation	151:163	arg1	NA	NA				Cterm		NA	4758		Glycosylation of the hemagglutinin (HA) and neuraminidase (NA) of the influenza provides crucial means for immune evasion and viral fitness in a host population.
29642453	1	58	gly	Glycosylation	151:163	arg1	neuraminidase	neuraminidase				PUBTATOR		neuraminidase	4758		Glycosylation of the hemagglutinin (HA) and neuraminidase (NA) of the influenza provides crucial means for immune evasion and viral fitness in a host population.
31098625	10	15	gly	A	1747:1747	arg1	Fucosylated glycans	secretory immunoglobulin A			Fucosylated glycans	Cterm		secretory immunoglobulin A			Fucosylated glycans of lactoferrin and high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans of secretory immunoglobulin A increased during lactation even when the concentrations of the parent proteins decreased.
31098625	10	15	gly	A	1747:1747	arg1	high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans	secretory immunoglobulin A			high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans	Cterm		secretory immunoglobulin A			Fucosylated glycans of lactoferrin and high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans of secretory immunoglobulin A increased during lactation even when the concentrations of the parent proteins decreased.
31098625	10	67	gly	lactoferrin	1605:1615	arg1	Fucosylated glycans	lactoferrin			Fucosylated glycans	OGER		lactoferrin	P02788		Fucosylated glycans of lactoferrin and high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans of secretory immunoglobulin A increased during lactation even when the concentrations of the parent proteins decreased.
31098625	10	67	gly	lactoferrin	1605:1615	arg1	high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans	lactoferrin			high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans	OGER		lactoferrin	P02788		Fucosylated glycans of lactoferrin and high-mannose, undecorated, fucosylated, sialylated, and combined fucosylated + sialylated glycans of secretory immunoglobulin A increased during lactation even when the concentrations of the parent proteins decreased.
31381874	4	71	gly	glycans	875:881	arg1	the IgM	IgM			glycans	OGER		IgM	P01871		As existing methods for the development and characterization of IgG-ADCs are not compatible with IgM-ADC, we describe a platform methodology suitable for site specific IgM-ADC using a chemoenzymatic method targeting the glycans on the IgM.
30315106	8	47	gly	glycoprotein	1338:1349	arg1	the CEL glycoprotein	the CEL glycoprotein				OGER		CEL glycoprotein	P19835		To examine whether the CEL glycoprotein might be modified by blood group antigens, we used high-sensitivity MALDI-TOF MS to characterize the released O-glycan pool of CEL immunoprecipitated from human pancreatic juice.
30315106	8	76	gly	CEL	1478:1480	arg1	the released O-glycan pool	CEL			the released O-glycan pool	PUBTATOR		CEL	P19835		To examine whether the CEL glycoprotein might be modified by blood group antigens, we used high-sensitivity MALDI-TOF MS to characterize the released O-glycan pool of CEL immunoprecipitated from human pancreatic juice.
31521285	5	5	gly	chain	975:979	arg1	Araf-(1→5)-Dha	side chain D			Araf-(1→5)-Dha	Cterm		side chain D			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
31521285	5	16	gly	chain	909:913	arg1	aceric acid-containing nonasaccharide	side chain B			aceric acid-containing nonasaccharide	Cterm		side chain B			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
31521285	5	19	gly	side	850:853	arg1	an uronic acid-rich octasaccharide	side chain A			an uronic acid-rich octasaccharide	Cterm		side chain A			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
31521285	5	24	gly	side	904:907	arg1	aceric acid-containing nonasaccharide	side chain B			aceric acid-containing nonasaccharide	Cterm		side chain B			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
31521285	5	29	gly	chain	855:859	arg1	an uronic acid-rich octasaccharide	side chain A			an uronic acid-rich octasaccharide	Cterm		side chain A			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
31521285	5	32	gly	side	970:973	arg1	Araf-(1→5)-Dha	side chain D			Araf-(1→5)-Dha	Cterm		side chain D			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
31521285	5	51	gly	side	935:938	arg1	Rhap-(1→5)-Kdo	side chain C			Rhap-(1→5)-Kdo	Cterm		side chain C			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
31521285	5	52	gly	chain	940:944	arg1	Rhap-(1→5)-Kdo	side chain C			Rhap-(1→5)-Kdo	Cterm		side chain C			The results indicate that HBE-III is composed of a main chain with a α-(1→4)-galacturono-oligosaccharide unit and four groups of side chains including an uronic acid-rich octasaccharide (side chain A), aceric acid-containing nonasaccharide (side chain B), Rhap-(1→5)-Kdo (side chain C), and Araf-(1→5)-Dha (side chain D), which is characteristic of rhamnogalacturonan II.
29767770	3	34	gly	PGM	899:901	arg1	the carbohydrate moiety	PGM			the carbohydrate moiety	OGER		PGM	P13611		The importance of the carbohydrate moiety of the F. oxysporum PGM was demonstrated.
30463578	0	91	gly	N-glycosylation	0:14	arg1	immunoglobulin G	immunoglobulin G				Cterm		immunoglobulin G			N-glycosylation patterns of plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease.
29975661	7	6	gly	glycosylated	912:923	arg1	glycosylated pro-KLKs 4 and 11	glycosylated pro-KLKs 4 and 11				PUBTATOR	AminoAcid	KLKs 4	11012		Activation of glycosylated pro-KLKs 4 and 11 turned out to be most efficient by glycosylated KLK2 and KLK4, respectively.
29975661	7	48	gly	glycosylated	978:989	arg1	glycosylated KLK2	glycosylated KLK2				PUBTATOR		KLK2	3817		Activation of glycosylated pro-KLKs 4 and 11 turned out to be most efficient by glycosylated KLK2 and KLK4, respectively.
31719144	6	28	gly	glycoprotein	693:704	arg1	MPO	MPO				PUBTATOR		MPO	4353		MPO is a homodimeric glycoprotein, posttranslationally modified with complex sugars at specific sites.
30772453	2	42	gly	clusters	428:435	arg1	K-12	K-12			clusters	OGER		K-12	Q8WVN6		Here, we describe a glyco-recoding strategy whereby major non-essential polysaccharide gene clusters in K-12 Escherichia coli are replaced with orthogonal glycosylation components for both biosynthesis of heterologous glycan structures and site-specific glycan conjugation to target proteins.
30325416	1	12	gly	glycosylation	114:126	arg1	human immunoglobulins G (IgGs)	human immunoglobulins G (IgGs)				Cterm		IgG			Fc glycosylation of human immunoglobulins G (IgGs) is essential for their structural integrity and activity.
31423004	0	47	gly	Antithrombin	50:61	arg1	the Oligosaccharide Structures	Antithrombin			the Oligosaccharide Structures	PUBTATOR		Antithrombin	462		A Comparison of the Oligosaccharide Structures of Antithrombin Derived from Plasma and Recombinant Using POTELLIGENT® Technology.
30315106	10	78	gly	glycoprotein	1754:1765	arg1	CEL	CEL				PUBTATOR		CEL	P19835		Thus, among digestive enzymes secreted by the pancreas, CEL is a glycoprotein with some unique characteristics, supporting the view that it could serve additional biological functions to its cholesteryl esterase activity in the duodenum.
30904681	0	11	gly	glycosylation	66:78	arg1	B2GP1	B2GP1				PUBTATOR		B2GP1	350		Simultaneous characterization of SNPs and N-glycans from multiple glycosylation sites of intact β-2-glycoprotein-1 (B2GP1) by ESI-qTOF-MS.
30904681	0	11	gly	glycosylation	66:78	arg1	intact β-2-glycoprotein-1	intact β-2-glycoprotein-1				PUBTATOR		-2-glycoprotein-1	350		Simultaneous characterization of SNPs and N-glycans from multiple glycosylation sites of intact β-2-glycoprotein-1 (B2GP1) by ESI-qTOF-MS.
31362986	2	32	gly	IgA2	297:300	arg1	N-glycan modifications	IgA2			N-glycan modifications	OGER		IgA2	P01877		Little is known about the impact of N-glycan modifications of IgA1 and IgA2 on binding to the Fcα receptor (FcαRI), which is also heavily glycosylated at its extracellular domain.
31362986	2	40	gly	IgA1	288:291	arg1	N-glycan modifications	IgA1			N-glycan modifications	PUBTATOR		IgA1	P01876		Little is known about the impact of N-glycan modifications of IgA1 and IgA2 on binding to the Fcα receptor (FcαRI), which is also heavily glycosylated at its extracellular domain.
31362986	2	82	gly	glycosylated	364:375	arg1	FcαRI	FcαRI				PUBTATOR		FcαRI	2204		Little is known about the impact of N-glycan modifications of IgA1 and IgA2 on binding to the Fcα receptor (FcαRI), which is also heavily glycosylated at its extracellular domain.
31362986	2	82	gly	glycosylated	364:375	arg1	the Fcα receptor	the Fcα receptor				PUBTATOR		Fcα receptor	2204		Little is known about the impact of N-glycan modifications of IgA1 and IgA2 on binding to the Fcα receptor (FcαRI), which is also heavily glycosylated at its extracellular domain.
29587225	3	51	gly	sialylation	439:449	arg1	EPO conformation	EPO conformation				PUBTATOR		EPO	2056		Nonetheless, a detailed understanding of the effects of sialylation on EPO conformation and dynamics is still lacking.
31500407	1	31	gly	glycoproteins	136:148	arg1	customized mucin glycoproteins	customized mucin glycoproteins				PUBTATOR		mucin glycoproteins	100508689		Few approaches exist for the stable and controllable synthesis of customized mucin glycoproteins for glycocalyx editing in eukaryotic cells.
31423004	5	49	gly	has	729:731	arg1	The rhAT AND mannose 6-phosphate	The rhAT			mannose 6-phosphate	Cterm		rhAT			The rhAT has more variable glycan structures, such as tetra-antennary complex type, high-mannose type, and mannose 6-phosphate species as minor components compared to plasma-derived human AT (phAT).
31423004	5	49	gly	has	729:731	arg1	The rhAT AND more variable glycan structures	The rhAT			more variable glycan structures	Cterm		rhAT			The rhAT has more variable glycan structures, such as tetra-antennary complex type, high-mannose type, and mannose 6-phosphate species as minor components compared to plasma-derived human AT (phAT).
31423004	5	49	gly	has	729:731	arg1	The rhAT AND tetra-antennary complex type	The rhAT			tetra-antennary complex type	Cterm		rhAT			The rhAT has more variable glycan structures, such as tetra-antennary complex type, high-mannose type, and mannose 6-phosphate species as minor components compared to plasma-derived human AT (phAT).
31423004	5	49	gly	has	729:731	arg1	The rhAT AND high-mannose type	The rhAT			high-mannose type	Cterm		rhAT			The rhAT has more variable glycan structures, such as tetra-antennary complex type, high-mannose type, and mannose 6-phosphate species as minor components compared to plasma-derived human AT (phAT).
30315106	0	91	gly	contains	62:69	arg1	pancreatic carboxyl-ester lipase AND core 1/core 2 O-glycans	pancreatic carboxyl-ester lipase		The mucinous domain	core 1/core 2 O-glycans	PUBTATOR		carboxyl-ester lipase	P19835	domain	The mucinous domain of pancreatic carboxyl-ester lipase (CEL) contains core 1/core 2 O-glycans that can be modified by ABO blood group determinants.
30525457	0	88	gly	IgG	38:40	arg1	the N-Glycan Composition	IgG			the N-Glycan Composition	Cterm		IgG			Profiling the N-Glycan Composition of IgG with Lectins and Capillary Nanogel Electrophoresis.
30999248	16	67	gly	released	2376:2383	arg1	glycoprotein mAb AND glycans	glycoprotein mAb			glycans	Cterm		mAb			We further successfully applied our approach to profiling and subsequent structure assignment of glycans released from glycoprotein mAb, which was in perfect agreement with previous studies and CE analysis.
30737276	2	70	gly	glycosylate	380:390	arg1	MCP	MCP				PUBTATOR		MCP	917865		Unlike most other viruses, PBCV-1 encodes most, if not all, of the machinery required to glycosylate its major capsid protein (MCP).
30737276	2	70	gly	glycosylate	380:390	arg1	its major capsid protein	its major capsid protein				PUBTATOR		major capsid protein	917865		Unlike most other viruses, PBCV-1 encodes most, if not all, of the machinery required to glycosylate its major capsid protein (MCP).
30904681	1	52	gly	glycosylated	150:161	arg1	B2GP1	B2GP1				PUBTATOR		B2GP1	350		The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites.
30904681	1	52	gly	glycosylated	150:161	arg1	also called apolipoprotein H	also called apolipoprotein H				PUBTATOR		apolipoprotein H	350		The highly glycosylated ß-2-glycoprotein-1 (B2GP1), also called apolipoprotein H, is a 50 kDa human plasma protein with four or five N-glycosylation sites.
29632092	6	48	gly	glycosylation	1804:1816	arg1	LTA	LTA				OGER		LTA	P01374		We show that while wild-type S. aureus LTA has only a trace of GlcNAcylated LTA under normal growth conditions, amounts are raised upon either overexpressing CsbB, reducing endogenous d-alanylation activity, expressing the cell envelope stress responsive alternative sigma factor SigB, or by exposure to environmental stress-inducing culture conditions, including growth media containing high levels of sodium chloride.IMPORTANCE The role of glycosylation in the structure and function of Staphylococcus aureus lipoteichoic acid (LTA) is largely unknown.
30348313	8	37	gly	demannosylation	1052:1066	arg1	R-TBN1	R-TBN1				PUBTATOR		TBN1	100037736		The partial demannosylation of R-TBN1 did not affect the nuclease activity; moreover, a little shift in substrate specificity was observed.
30348313	8	66	gly	R-TBN1	1071:1076	arg1	The partial demannosylation	TBN1			The partial demannosylation	PUBTATOR		TBN1	100037736		The partial demannosylation of R-TBN1 did not affect the nuclease activity; moreover, a little shift in substrate specificity was observed.
29343515	4	50	gly	glycosylation	661:673	arg1	LTA	LTA				OGER		LTA	P01374		However, the function of and proteins responsible for the glycosylation of LTA are either unknown or not well-characterized.
31881468	0	12	gly	glycoprotein	74:85	arg1	myelin oligodendrocyte glycoprotein	myelin oligodendrocyte glycoprotein				PUBTATOR		myelin oligodendrocyte glycoprotein	4340		A comparative study for the intermediate states of myelin oligodendrocyte glycoprotein in the absence and presence of glycan - A computational approach.
29769321	0	24	gly	D	71:71	arg1	sialoglycans	protein D			sialoglycans	OGER		protein D	Q13268		Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus.
31531180	0	33	gly	Tea	92:94	arg1	Polysaccharides	Mist Tea			Polysaccharides	OGER		Mist Tea	Q7Z7G1		Chemical Composition and Antioxidant Activities of Polysaccharides from Yingshan Cloud Mist Tea.
31501225	6	46	gly	glycopeptides	973:985	arg1	IgA2	IgA2				OGER		IgA2	P01877		TPLTAN205ITK (H5N5S1F1) and (H5N4S2F1) corresponding to the glycopeptides of IgA2 were significantly elevated in serum from patients with HBV infection and even higher in HBV-related LC patients, as compared with healthy donor.
30990348	9	39	gly	glutathione	2218:2228	arg1	N-acetylglucosamine	glutathione S-transferase			N-acetylglucosamine	PUBTATOR		glutathione S-transferase	373156		Abbreviations: ABC, ammonium bicarbonate solution; ACN, acetonitrile; ADCC, antibody-dependent cell-mediated cytotoxicity; C1q, complement component 1q; CDC, complement-dependent cytotoxicity; CQA, critical quality attribute; Endo, endo-β-N-acetylglucosaminidase; FA, formic acid; Fc, crystallizable fragment; FcγR, Fcγ receptors; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; GST, glutathione S-transferase; HER2, human epidermal growth factor receptor 2; HDX, hydrogen-deuterium exchange; HILIC, hydrophilic interaction liquid chromatography; HLB-SPE, hydrophilic-lipophilic balance-solid-phase extraction; HPLC, high-performance liquid chromatography; mAb, monoclonal antibody; Man, mannose; MS, mass spectrometry; PBS, phosphate-buffered saline; SGP, hen egg yolk sialylglycopeptides.
30990348	9	47	gly	growth	2267:2272	arg1	N-acetylglucosamine	epidermal growth factor receptor 2			N-acetylglucosamine	PUBTATOR		epidermal growth factor receptor 2	2064		Abbreviations: ABC, ammonium bicarbonate solution; ACN, acetonitrile; ADCC, antibody-dependent cell-mediated cytotoxicity; C1q, complement component 1q; CDC, complement-dependent cytotoxicity; CQA, critical quality attribute; Endo, endo-β-N-acetylglucosaminidase; FA, formic acid; Fc, crystallizable fragment; FcγR, Fcγ receptors; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; GST, glutathione S-transferase; HER2, human epidermal growth factor receptor 2; HDX, hydrogen-deuterium exchange; HILIC, hydrophilic interaction liquid chromatography; HLB-SPE, hydrophilic-lipophilic balance-solid-phase extraction; HPLC, high-performance liquid chromatography; mAb, monoclonal antibody; Man, mannose; MS, mass spectrometry; PBS, phosphate-buffered saline; SGP, hen egg yolk sialylglycopeptides.
30990348	9	53	gly	epidermal	2257:2265	arg1	N-acetylglucosamine	epidermal growth factor receptor 2			N-acetylglucosamine	PUBTATOR		epidermal growth factor receptor 2	2064		Abbreviations: ABC, ammonium bicarbonate solution; ACN, acetonitrile; ADCC, antibody-dependent cell-mediated cytotoxicity; C1q, complement component 1q; CDC, complement-dependent cytotoxicity; CQA, critical quality attribute; Endo, endo-β-N-acetylglucosaminidase; FA, formic acid; Fc, crystallizable fragment; FcγR, Fcγ receptors; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; GST, glutathione S-transferase; HER2, human epidermal growth factor receptor 2; HDX, hydrogen-deuterium exchange; HILIC, hydrophilic interaction liquid chromatography; HLB-SPE, hydrophilic-lipophilic balance-solid-phase extraction; HPLC, high-performance liquid chromatography; mAb, monoclonal antibody; Man, mannose; MS, mass spectrometry; PBS, phosphate-buffered saline; SGP, hen egg yolk sialylglycopeptides.
30990348	9	58	gly	factor	2274:2279	arg1	N-acetylglucosamine	epidermal growth factor receptor 2			N-acetylglucosamine	PUBTATOR		epidermal growth factor receptor 2	2064		Abbreviations: ABC, ammonium bicarbonate solution; ACN, acetonitrile; ADCC, antibody-dependent cell-mediated cytotoxicity; C1q, complement component 1q; CDC, complement-dependent cytotoxicity; CQA, critical quality attribute; Endo, endo-β-N-acetylglucosaminidase; FA, formic acid; Fc, crystallizable fragment; FcγR, Fcγ receptors; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; GST, glutathione S-transferase; HER2, human epidermal growth factor receptor 2; HDX, hydrogen-deuterium exchange; HILIC, hydrophilic interaction liquid chromatography; HLB-SPE, hydrophilic-lipophilic balance-solid-phase extraction; HPLC, high-performance liquid chromatography; mAb, monoclonal antibody; Man, mannose; MS, mass spectrometry; PBS, phosphate-buffered saline; SGP, hen egg yolk sialylglycopeptides.
29580922	11	75	gly	N-glycans	1703:1711	arg1	haptoglobin	haptoglobin			N-glycans	PUBTATOR		haptoglobin	3240		CONCLUSIONS: Tri-antennary and sialylated N-glycans on haptoglobin at the Asn207 and Asn211 sites were abundant in SSCs and characteristic of extreme human longevity.
30414905	5	10	gly	APS	944:946	arg1	the monosaccharide composition	APS			the monosaccharide composition	OGER		APS	P07288		Moreover, UPLC/Q-TOF-MS fingerprints were established based on the monosaccharide composition of the APS.
30348313	0	40	gly	N-glycosylation	0:14	arg1	tomato nuclease TBN1	tomato nuclease TBN1				PUBTATOR		TBN1	100037736		N-glycosylation of tomato nuclease TBN1 produced in N. benthamiana and its effect on the enzyme activity.
31882545	4	0	gly	glycosylation	618:630	arg1	the phosphate-regulating hormone fibroblast growth factor 23	the phosphate-regulating hormone fibroblast growth factor 23				PUBTATOR		fibroblast growth factor 23	8074		In HFTC, loss of GALNT3 activity in the bone is thought to lead to altered glycosylation of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), resulting in hyperphosphatemia and subdermal calcified tumors.
31882545	4	0	gly	glycosylation	618:630	arg1	FGF23	FGF23				PUBTATOR		FGF23	8074		In HFTC, loss of GALNT3 activity in the bone is thought to lead to altered glycosylation of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), resulting in hyperphosphatemia and subdermal calcified tumors.
29858715	4	31	gly	N-glycosylation	536:550	arg1	PIP	PIP				PUBTATOR		PIP	5304		Here, we present the analysis of the N-glycosylation of PIP isolated from different sources by LC-MS(/MS) and 1H-NMR.
30959980	6	18	gly	detected	1125:1132	arg2	rabbit intestinal mucin AND sulfated-sialylated glycans	rabbit intestinal mucin			sulfated-sialylated glycans	PUBTATOR		mucin	100508689		Sulfated glycans accounted for 58%, unique disufated and sulfated-sialylated glycans were also detected in rabbit intestinal mucin.
30959980	6	18	gly	detected	1125:1132	arg2	rabbit intestinal mucin AND Sulfated glycans	rabbit intestinal mucin			Sulfated glycans	PUBTATOR		mucin	100508689		Sulfated glycans accounted for 58%, unique disufated and sulfated-sialylated glycans were also detected in rabbit intestinal mucin.
29767770	5	67	gly	de-O-glycosylated	1042:1058	arg1	de-O-glycosylated PGM	de-O-glycosylated PGM				OGER		PGM	P13611		A strong decrease in reactivity was also observed with de-O-glycosylated PGM.
29620509	10	97	gly	deglycosylated	1617:1630	arg1	deglycosylated Necl-4 protein	deglycosylated Necl-4 protein				PUBTATOR		Necl-4 protein	199731		By adding mannosidase inhibitor kifunensine into the medium and cutting purified protein by using endoglycosidase H, we can obtain deglycosylated Necl-4 protein in milligram quantities.
30904681	9	12	gly	B2GP1	1411:1415	arg1	glycan compositions	B2GP1			glycan compositions	PUBTATOR		B2GP1	350		Our method allows a fast determination of genetic variants and glycan compositions of human B2GP1 to be potentially used as diagnostic marker.
30084397	0	53	gly	glycosylated	28:39	arg1	highly glycosylated human leukocyte elastase	highly glycosylated human leukocyte elastase				PUBTATOR		leukocyte elastase	1991		Crystal structure of highly glycosylated human leukocyte elastase in complex with an S2' site binding inhibitor.
30513349	7	24	gly	rhA1AT	1152:1157	arg1	the N-linked glyco-structures	A1AT			the N-linked glyco-structures	PUBTATOR		A1AT	5265		We were able to show that the N-linked glyco-structures of rhA1AT and rhC1INH are homogeneous and similar to the structures obtained from plasma-derived A1AT and C1INH, marketed as Prolastin®-C and Cinryze®, respectively.
30513349	7	77	gly	rhC1INH	1163:1169	arg1	the N-linked glyco-structures	C1INH			the N-linked glyco-structures	PUBTATOR		C1INH	710		We were able to show that the N-linked glyco-structures of rhA1AT and rhC1INH are homogeneous and similar to the structures obtained from plasma-derived A1AT and C1INH, marketed as Prolastin®-C and Cinryze®, respectively.
29618644	7	22	gly	helices	1327:1333	arg1	gp41	gp41			helices	Cterm		gp41			The resulting structure revealed that the heptad repeat helices in gp41 are drawn in close proximity to the trimer axis and that gp120 protomers also showed a relatively compact disposition around the trimer axis.
31877766	1	80	gly	glycoprotein	101:112	arg1	Osteopontin	Osteopontin				PUBTATOR		Osteopontin	6696		Osteopontin (OPN) is a matrix glycoprotein of urinary calculi.
30513259	1	71	gly	glycan	178:183	arg1	immunoglobulin G	immunoglobulin G			glycan	Cterm		immunoglobulin G			The N-linked glycan in immunoglobulin G is critical for the stability and function of the crystallizable fragment (Fc) region.
31246420	0	46	gly	Lubricin	141:148	arg1	the Complete Detectable O-Glycan Repertoire	Lubricin			the Complete Detectable O-Glycan Repertoire	PUBTATOR		Lubricin	10216		Deciphering Isomers with a Multiple Reaction Monitoring Method for the Complete Detectable O-Glycan Repertoire of the Candidate Therapeutic, Lubricin.
29595997	2	25	gly	protein	388:394	arg1	the numerous glycans	envelope protein			the numerous glycans	PUBTATOR		envelope protein	64006		Importantly, these bnAbs have evolved to recognize not only the two protein components of the viral envelope protein (Env) but also the numerous glycans that form a protective barrier on the Env protein.
31888963	3	44	part_of	CD16a	542:546	arg1	N162	CD16a		N162		PUBTATOR	SpecificSite	CD16a	2214	N162	Furthermore, post-translational modification impacts antibody binding affinity, most notably the composition of the asparagine(N)-linked glycan at N162 of CD16a.
29975661	4	19	gly	glycosylated	509:520	arg1	glycosylated prostatic KLKs	glycosylated prostatic KLKs				PUBTATOR		KLKs	11012		In order to study glycosylated prostatic KLKs resembling the natural proteases, we used Leishmania (LEXSY) and HEK293 cells for secretory expression.
29617676	0	29	gly	Glycosylation	0:12	arg1	Human IgA	Human IgA				PUBTATOR		IgA	973		Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses.
30770394	1	37	gly	determinants	105:116	arg1	VWF	VWF			determinants	PUBTATOR		VWF	7450		Glycan determinants on von Willebrand factor (VWF) play critical roles in regulating its susceptibility to proteolysis and clearance.
30770394	1	37	gly	determinants	105:116	arg1	von Willebrand factor	von Willebrand factor			determinants	PUBTATOR		von Willebrand factor	7450		Glycan determinants on von Willebrand factor (VWF) play critical roles in regulating its susceptibility to proteolysis and clearance.
29580922	8	0	gly	haptoglobin	1375:1385	arg1	tri-antennary and sialylated N-glycans	haptoglobin			tri-antennary and sialylated N-glycans	PUBTATOR		haptoglobin	3240		Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
30315106	6	88	gly	glycoisoform	926:937	arg1	CEL	CEL				PUBTATOR		CEL	P19835		CEL was not detectably expressed in neoplastic cells, implying that FAPP is unlikely to be a glycoisoform of CEL in pancreatic cancer.
30563843	3	54	gly	glycosylated	438:449	arg1	glycosylated human AGT	glycosylated human AGT				PUBTATOR		AGT	183		Here, we solved the crystal structures of glycosylated human AGT (2.30 Å resolution), its encounter complex with renin (2.55 Å), AGT cleaved in its reactive center loop (RCL; 2.97 Å), and spent AGT from which the N-terminal angiotensin peptide was removed (2.63 Å).
29775210	0	71	gly	N-glycosylation	47:61	arg1	human immunoglobulin G1	human immunoglobulin G1				Cterm		immunoglobulin G1			The effect of simulated space radiation on the N-glycosylation of human immunoglobulin G1.
29578022	6	34	gly	observed	1182:1189	arg1	T-SP AND the di-sulfated Fuc residue	T-SP			the di-sulfated Fuc residue	Cterm		T-SP	P49903		As indicated by the results, fucan to fucosylated chondroitin sulfate ratio was found high in A-SP compared to T-SP, fucan with a lower molecular weight was the major fraction in A-SP, and the di-sulfated Fuc residue observed in T-SP was absent in A-SP.
30564965	6	28	gly	Glycosylation	857:869	arg1	α2M	α2M				PUBTATOR		2M	2		Glycosylation of α2M and its reactivity with IGFBP-2 is similarly affected by ageing and incidence of colon cancer, but the reactivity of α2M with Zn ions is differently affected, as the binding of Zn ions remains unaltered in patients with colon cancer compared to healthy middle-aged individuals.
31751705	7	18	gly	Concanavalin	1605:1616	arg1	mannose-binding protein	Concanavalin A			mannose-binding protein	Cterm		Concanavalin A			Furthermore, we confirmed that the neoglycopolymer carrying the multivalent high-mannose type N-glycans is a useful tool for rapid purification of mannose-binding protein, Concanavalin A, from jack bean extract.
30904681	2	5	gly	Glycosylation	295:307	arg1	B2GP1	B2GP1				PUBTATOR		B2GP1	350		Glycosylation of B2GP1 can impact auto antibody recognition leading to the development of antiphospholipid syndrome (APS), which can result in miscarriages or thrombosis.
29790762	0	0	gly	B	100:100	arg1	the Branched Trisaccharide Fragment	the Antibiotic Saccharomicin B			the Branched Trisaccharide Fragment	Cterm		the Antibiotic Saccharomicin B			Reagent-Controlled Synthesis of the Branched Trisaccharide Fragment of the Antibiotic Saccharomicin B.
29915149	4	94	gly	AAV	726:728	arg1	glycans	AAV			glycans	Cterm		AAV			Significantly, all primary AAV receptors of the virus are glycans.
31100702	10	61	gly	lactoferrin	1160:1170	arg1	the glycans	lactoferrin			the glycans	PUBTATOR		lactoferrin	280846		Recovery of the glycans from lactoferrin was, however, much lower when utilizing acetone precipitation versus the polystyrene resin; 52% versus 85% respectively.
31169903	3	104	gly	glycoforms	433:442	arg1	The circulating TSH glycoforms	The circulating TSH glycoforms				OGER		TSH			The circulating TSH glycoforms and their glycan compositions in young children have hitherto not been determined.
30016589	6	19	gly	fucosylated	1234:1244	arg1	fucosylated IgG1 Fc binding CD16a	fucosylated IgG1 Fc binding CD16a				PUBTATOR		CD16a	2214		The effects of fucosylation on IgG1 Fc may account for the remaining 0.5 ± 0.1 kcal/mol penalty of fucosylated IgG1 Fc binding CD16a when compared to that of afucosylated IgG1 Fc.
30016589	6	21	gly	fucosylation	1150:1161	arg1	IgG1 Fc	IgG1 Fc				OGER		IgG1	P01857		The effects of fucosylation on IgG1 Fc may account for the remaining 0.5 ± 0.1 kcal/mol penalty of fucosylated IgG1 Fc binding CD16a when compared to that of afucosylated IgG1 Fc.
30624066	6	49	gly	glycoprotein	1134:1145	arg1	three human serum GPs	three human serum GPs				OGER		GPs			Implementation of the approach is illustrated using the known interactions between a C-terminal domain fragment of human galectin-3 (hGal-3C) and three human serum GPs, α-1-acid glycoprotein (AGP), haptoglobin phenotype 1-1 (Hp1-1) and α-2-macroglobulin (α2M).
30553311	1	58	gly	Haitanensis	241:251	arg1	extract polysaccharides	Haitanensis (PHP			extract polysaccharides	OGER		Haitanensis (PHP	Q9DAK9		Microwave assisted extraction (MAE) technology was used to extract polysaccharides from Porphyra Haitanensis (PHP) with water.
29881382	1	48	gly	glycoprotein	156:167	arg1	Env	Env				Cterm		Env	155971		Native flexibly linked (NFL) HIV-1 envelope glycoprotein (Env) trimers are cleavage-independent and display a native-like, well-folded conformation that preferentially displays broadly neutralizing determinants.
29881382	1	48	gly	glycoprotein	156:167	arg1	flexibly linked (NFL) HIV-1 envelope glycoprotein	flexibly linked (NFL) HIV-1 envelope glycoprotein				PUBTATOR		HIV-1 envelope glycoprotein	155971		Native flexibly linked (NFL) HIV-1 envelope glycoprotein (Env) trimers are cleavage-independent and display a native-like, well-folded conformation that preferentially displays broadly neutralizing determinants.
31362986	6	15	gly	glycoforms	1217:1226	arg1	four different FcαRI glycoforms	four different FcαRI glycoforms				PUBTATOR		FcαRI	2204		Using size-exclusion chromatography, differential scanning and isothermal titration calorimetry, surface plasmon resonance spectroscopy, and molecular modeling, we probed distinct IgA1 and IgA2 glycoforms for binding to four different FcαRI glycoforms and investigated the thermodynamics and kinetics of complex formation.
31362986	6	51	gly	glycoforms	1170:1179	arg1	IgA2	IgA2				OGER		IgA2	P01877		Using size-exclusion chromatography, differential scanning and isothermal titration calorimetry, surface plasmon resonance spectroscopy, and molecular modeling, we probed distinct IgA1 and IgA2 glycoforms for binding to four different FcαRI glycoforms and investigated the thermodynamics and kinetics of complex formation.
31362986	6	51	gly	glycoforms	1170:1179	arg1	distinct IgA1	distinct IgA1				PUBTATOR		IgA1	P01876		Using size-exclusion chromatography, differential scanning and isothermal titration calorimetry, surface plasmon resonance spectroscopy, and molecular modeling, we probed distinct IgA1 and IgA2 glycoforms for binding to four different FcαRI glycoforms and investigated the thermodynamics and kinetics of complex formation.
31623207	3	36	gly	had	327:329	arg1	PCp-I AND the same monosaccharide composition	PCp			the same monosaccharide composition	OGER		PCp	P42785		PCp-I and PCp-II had the same monosaccharide composition, but their molar ratios were different.
31611356	2	74	part_of	gp120	357:361	arg1	N295	gp120		N295		PUBTATOR	SpecificSite	gp120	3700	N295	A key factor for Grft potency is glycosylation at N295 of gp120, which is directly adjacent to N332, a target glycan for an entire class of broadly neutralizing antibodies (bNAbs).
31289257	5	51	gly	glycosylation	868:880	arg1	microtubule-associated protein 6	microtubule-associated protein 6				PUBTATOR		microtubule-associated protein 6	17760		Subsequent lectin affinity chromatography coupled with mass spectrometry revealed enhanced glycosylation of microtubule-associated protein 6 (MAP6) in PD mice as compared to healthy controls.
31289257	5	51	gly	glycosylation	868:880	arg1	MAP6	MAP6				PUBTATOR		MAP6	17760		Subsequent lectin affinity chromatography coupled with mass spectrometry revealed enhanced glycosylation of microtubule-associated protein 6 (MAP6) in PD mice as compared to healthy controls.
29655002	6	20	gly	Gal	938:940	arg1	several carbohydrate moieties	Gal			several carbohydrate moieties	OGER		Gal	Q8N6F7		The results pointed to an increase in several carbohydrate moieties: tri/tetra-antennary structures, Gal β-1,4 GlcNAc, terminal α-2,3 Sia and α-1,3 Man, and a decrease in core α-1,6 Fuc and bi-antennary galactosylated N-glycans with bisecting GlcNAc.
29655002	6	30	gly	α-1,3	979:983	arg1	several carbohydrate moieties	-1			several carbohydrate moieties	PUBTATOR		-1	597		The results pointed to an increase in several carbohydrate moieties: tri/tetra-antennary structures, Gal β-1,4 GlcNAc, terminal α-2,3 Sia and α-1,3 Man, and a decrease in core α-1,6 Fuc and bi-antennary galactosylated N-glycans with bisecting GlcNAc.
29655002	6	63	gly	α-2,3	965:969	arg1	several carbohydrate moieties	-2			several carbohydrate moieties	PUBTATOR		-2	170589		The results pointed to an increase in several carbohydrate moieties: tri/tetra-antennary structures, Gal β-1,4 GlcNAc, terminal α-2,3 Sia and α-1,3 Man, and a decrease in core α-1,6 Fuc and bi-antennary galactosylated N-glycans with bisecting GlcNAc.
29655002	6	69	gly	β-1,4	942:946	arg1	several carbohydrate moieties	-1			several carbohydrate moieties	PUBTATOR		-1	597		The results pointed to an increase in several carbohydrate moieties: tri/tetra-antennary structures, Gal β-1,4 GlcNAc, terminal α-2,3 Sia and α-1,3 Man, and a decrease in core α-1,6 Fuc and bi-antennary galactosylated N-glycans with bisecting GlcNAc.
29615747	5	24	gly	GPs	865:867	arg1	glycans	GPs			glycans	OGER		GPs			Furthermore, structural analysis of glycans of GPs revealed that N-glycans were more extended in REBOV than in ZEBOV.
29975661	8	21	gly	glycosylated	1037:1048	arg1	the glycosylated prostatic KLKs	the glycosylated prostatic KLKs				PUBTATOR		KLKs	11012		By comparing the glycosylated prostatic KLKs with their non-glycosylated counterparts from Escherichia coli, it was observed that the N-glycans stabilize the KLK proteases and change their activation profiles and their enzymatic activity to some extent.
30525457	1	68	gly	contains	117:124	arg1	Glycosylated human IgG AND fucosylated biantennary N-glycans	Glycosylated human IgG			fucosylated biantennary N-glycans	Cterm		IgG			Glycosylated human IgG contains fucosylated biantennary N-glycans with different modifications including N-acetylglucosamine, which bisects the mannose core.
30115684	1	29	gly	glycan	124:129	arg1	the envelope glycoprotein gp120	gp120			glycan	PUBTATOR		gp120	3700		The glycan shield on the envelope glycoprotein gp120 of human immunodeficiency virus 1 (HIV-1) has drawn immense attention as a vulnerable site for broadly neutralizing antibodies (bNAbs) and for its significant impact on host adaptive immune response to HIV-1.
31669606	10	68	gly	nonglycosylated	1363:1377	arg1	The nonglycosylated N297Q IgG4-Fc	The nonglycosylated N297Q IgG4-Fc				OGER		N297Q IgG4	P01861		The nonglycosylated N297Q IgG4-Fc did not present measurable affinity to FcγRIIIA.
31411531	7	101	gly	glycans	1322:1328	arg1	CHO-expressed IgG1	CHO-expressed IgG1			glycans	OGER		CHO-expressed IgG1	P01857		When structural isomers of sialylated glycans were chromatographically resolved and identified in the limited proteolysis experiment, we found that only alpha 2,3-linked sialic acid on the 6-arm (the major sialylated glycans in CHO-expressed IgG1) destabilizes the CH2 domain, presumably because of the steric effect that decreases the glycan-CH2 domain interaction.
29975661	6	60	gly	glycosylation	869:881	arg1	these KLKs	these KLKs				PUBTATOR		KLKs	11012		Periodic acid-Schiff reaction, enzymatic deglycosylation assays, and mass spectrometry confirmed the glycosylation of these KLKs.
31888812	3	27	gly	contained	563:571	arg1	ARPP-40 AND glucose	ARPP-40			glucose	OGER		ARPP	Q9GZV1		In terms of monosaccharide composition, ARPP-40 contained only glucose, while ARPP-70 was composed of seven monosaccharides, of which glucose and galactose were the main components.
29888905	3	63	gly	glycoproteins	566:578	arg1	human HEK-293	human HEK-293				OGER		HEK	P29320		Here, we describe a strategy for high-resolution quantitative profiling and structure elucidation of N-glycans from EV glycoproteins of three cell lines: human HEK-293, human glioma H4 and mouse glioma Tu-2449.
30641224	2	2	gly	N-glycosylation	295:309	arg1	human plasma HDL	human plasma HDL				OGER		HDL	Q9UNE0		We assessed N-glycosylation of human plasma HDL and LDL and the role of their glycomes in cellular cholesterol metabolism.
31316527	8	123	gly	glycoform	1334:1342	arg1	the predominant full-length rCMG2-Fc glycoform	the predominant full-length rCMG2-Fc glycoform				OGER		CMG2			In parallel, we performed molecular dynamics (MD) simulations of the predominant full-length rCMG2-Fc glycoform for each of the three N-glycosylation profiles to understand the effects of glycosylation at the molecular level.
30513259	3	11	gly	glycosylated	557:568	arg1	gFc	gFc				Cterm		Fc			To confirm this hypothesis, we examined the small-angle X-ray scattering (SAXS) profile of the glycosylated Fc region (gFc) and aglycosylated Fc region (aFc) in solution.
30513259	3	53	gly	aglycosylated	590:602	arg1	aFc	aFc				Cterm		Fc			To confirm this hypothesis, we examined the small-angle X-ray scattering (SAXS) profile of the glycosylated Fc region (gFc) and aglycosylated Fc region (aFc) in solution.
31877766	2	56	gly	glycosylation	183:195	arg1	OPN	OPN				PUBTATOR		OPN	6696		This study aims to identify the role of aberrant glycosylation of OPN in urolithiasis.
30842877	4	61	gly	IgA1	870:873	arg1	the O-linked glycan preparations	IgA1			the O-linked glycan preparations	PUBTATOR		IgA1	P01876		Detailed mass spectrometric structural analysis showed an increase in disialo-biantennary N-linked glycans on IgA1 from BCa patients (p < 0.0001: non-core fucosylated; p = 0.0345: core fucosylated) and increased asialo-Thomsen-Friedenreich antigen (TF) and disialo-TF antigens in the O-linked glycan preparations from IgA1 of cancer patients compared with healthy control individuals.
30669833	3	92	gly	structures	729:738	arg1	PSA	PSA			structures	PUBTATOR		PSA	354		As a result of analysis using sera from 15 PCa or 15 benign prostate hyperplasia (BPH) patients whose PSA levels were in the "gray zone" (4.0-10.0 ng/mL), 52 glycan structures on PSA were quantitatively observed.
29370305	1	82	gly	glycoprotein	121:132	arg1	Env	Env				PUBTATOR		Env	100616444		HIV-1 envelope glycoprotein (Env) mediates virus attachment and entry into the host cells.
29881382	6	66	gly	present	1197:1203	arg1	the BG505 Env AND the N-glycan "hole"	the BG505 Env			the N-glycan "hole"	Cterm		BG505 Env	155971		These antibodies targeted the N-glycan "hole" naturally present on the BG505 Env proximal to residues at positions 230, 241, and 289.
30902814	5	94	gly	N-glycosylation	708:722	arg1	the M41-RBD	the M41-RBD				PUBTATOR		M41			Ten single Asn-to-Ala substitutions at the predicted N-glycosylation sites of the M41-RBD were evaluated along with two control Val-to-Ala substitutions.
30335821	2	35	gly	glycosylation	705:717	arg1	Env	Env				PUBTATOR		Env	155971		To optimize the expression and immunogenicity of the yeast-displayed Env protein, we tested different approaches for cell wall anchoring, expression of gp120 and gp140 Env from different viral strains, the effects of introducing mutations designed to stabilize Env, and the effects of procedures for altering N-linked glycosylation of Env.
29674057	12	82	gly	glycoforms	2090:2099	arg1	rhEPO glycoforms	rhEPO glycoforms				OGER		rhEPO	P29676		Finally it was demonstrated that by replacing TFA for difluoroacetic acid, peak resolution somewhat decreased, but rhEPO glycoforms with relative abundances below 1% could be detected by HILIC-MS, increasing the overall rhEPO glycoform coverage to 72.
29444271	3	24	gly	Sl-2	723:726	arg1	anti-FLAG tag	α-Fuc'ase Sl-2			anti-FLAG tag	OGER		α-Fuc'ase Sl-2	P09238		The baculovirus-insect cell expression system was used to express that α-Fuc'ase Sl-2 with anti-FLAG tag, and the expression product (rFuc'ase Sl-2), was found as a 65 kDa protein using SDS-PAGE and has an optimum pH of around 5.0.
30348313	5	12	gly	deglycosylated	726:739	arg1	R-TBN1	R-TBN1				PUBTATOR		TBN1	100037736		To monitor the role of N-glycosylation in its activity, hypo- and hyperglycosylated nuclease mutants, R-TBN1 digested by α-mannosidase, and R-TBN1 deglycosylated by PNGase F were prepared.
30281305	0	38	gly	Impact	58:63	arg1	Wine Polysaccharide	Impact			Wine Polysaccharide	OGER		Impact	Q9P2X3		Preharvest Application of Elicitors to Monastrell Grapes: Impact on Wine Polysaccharide and Oligosaccharide Composition.
30281305	0	38	gly	Impact	58:63	arg1	Oligosaccharide Composition	Impact			Oligosaccharide Composition	OGER		Impact	Q9P2X3		Preharvest Application of Elicitors to Monastrell Grapes: Impact on Wine Polysaccharide and Oligosaccharide Composition.
31393126	9	94	gly	attached	1435:1442	arg2	MRJP2 AND 18, 17, and 2 N-glycans	MRJP2			18, 17, and 2 N-glycans	PUBTATOR		MRJP2	406091		There were 18, 17, and 2 N-glycans attached to MRJP1, MRJP2, and MRJP3, respectively.
31393126	9	94	gly	attached	1435:1442	arg2	MRJP3 AND 18, 17, and 2 N-glycans	MRJP3			18, 17, and 2 N-glycans	PUBTATOR		MRJP3	406121		There were 18, 17, and 2 N-glycans attached to MRJP1, MRJP2, and MRJP3, respectively.
31393126	9	94	gly	attached	1435:1442	arg1	MRJP1 AND 18, 17, and 2 N-glycans	MRJP1			18, 17, and 2 N-glycans	PUBTATOR		MRJP1	406090		There were 18, 17, and 2 N-glycans attached to MRJP1, MRJP2, and MRJP3, respectively.
31719144	9	4	gly	attached	1131:1138	arg2	MPO AND the glycans	MPO			the glycans	PUBTATOR		MPO	4353		Although considered important for MPO structure and function, the full scope and relative abundance of the glycans attached to MPO is unknown.
30564965	0	58	gly	Alpha-2-Macroglobulin	49:69	arg1	the Glycan Structure	Alpha-2-Macroglobulin			the Glycan Structure	PUBTATOR		Alpha-2-Macroglobulin	2		Changes Due to Ageing in the Glycan Structure of Alpha-2-Macroglobulin and Its Reactivity with Ligands.
30612271	3	39	gly	glycoprotein	498:509	arg1	RAGE	RAGE				PUBTATOR		RAGE	177		RAGE, a type I transmembrane glycoprotein, was identified as a receptor for AGEs.
30578591	6	51	gly	glycosites	978:987	arg1	NA	NA				Cterm		NA	4758		Different types of glycans are identified from different glycosites of NA expressed in human cells, which implies the site-dependence of glycosylation on NA.
30080931	2	70	gly	antigens	434:441	arg1	g127+g138 or g83+g127+138 rH5HA	138 rH5HA			antigens	Cterm		138 rH5HA			We previously reported that glycan-masking recombinant H5 hemagglutin (rH5HA) antigens on residues 83, 127, and 138 (g127+g138 or g83+g127+138 rH5HA) elicited broader neutralizing antibodies and protection against heterologous clades/subclades of high pathogenic avian influenza H5N1 viruses.
30080931	2	70	gly	antigens	434:441	arg1	residues 83, 127, and 138			residues 83, 127, and 138	residues 83, 127, and 138		SpecificSite			residues 83, 127, and 138	We previously reported that glycan-masking recombinant H5 hemagglutin (rH5HA) antigens on residues 83, 127, and 138 (g127+g138 or g83+g127+138 rH5HA) elicited broader neutralizing antibodies and protection against heterologous clades/subclades of high pathogenic avian influenza H5N1 viruses.
31732167	1	30	gly	glycoprotein	229:240	arg1	Env	Env				PUBTATOR		Env	100616444		The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer remains a major vaccine challenge.
31732167	1	30	gly	glycoprotein	229:240	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				PUBTATOR		HIV-1 envelope glycoprotein	100616444		The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer remains a major vaccine challenge.
31057084	0	13	gly	glycoprotein	69:80	arg1	myelin oligodendrocyte glycoprotein	myelin oligodendrocyte glycoprotein				PUBTATOR		myelin oligodendrocyte glycoprotein	4340		Role of N-glycan in the structural changes of myelin oligodendrocyte glycoprotein and its complex with an antibody.
29775210	8	6	gly	carbohydrate	1440:1451	arg1	IgG1	IgG1				OGER		IgG1	P01857		Consequently, changes in N-linked carbohydrate profile of IgG1 can be used as molecular diagnostic tools in space.
29775210	8	15	gly	IgG1	1464:1467	arg1	N-linked carbohydrate profile	IgG1			N-linked carbohydrate profile	OGER		IgG1	P01857		Consequently, changes in N-linked carbohydrate profile of IgG1 can be used as molecular diagnostic tools in space.
30275012	3	1	gly	glycosylated	397:408	arg1	the S-layer	the S-layer				Cterm		S-layer			In many bacterial and archaeal species, the S-layer is glycosylated, but no such modifications have been demonstrated in C. difficile.
29330305	7	56	gly	glycoforms	1605:1614	arg1	the two CD16a glycoforms	the two CD16a glycoforms				PUBTATOR		CD16a	2214		The changes in binding activity mirrored changes in NMR spectra of the two CD16a glycoforms, indicating that CD16a glycan composition also affects the glycoprotein's structure.
30782654	12	73	gly	glycosylation	2516:2528	arg1	the surface protein GspA	the surface protein GspA				Cterm		GspA			Importantly, LcpA mediates glycosylation of the surface protein GspA via phosphotransferase activity.
30948514	3	51	gly	N-glycosylated	447:460	arg1	Human rhodopsin	Human rhodopsin				PUBTATOR		Human rhodopsin	6010		Human rhodopsin is N-glycosylated on Asn2 and Asn15, whereas human (h) red and green cone opsins (hOPSR and hOPSG, respectively) are N-glycosylated at Asn34 Here, utilizing a monoclonal antibody (7G8 mAB), we demonstrate that hOPSR and hOPSG from human retina also are O-glycosylated with full occupancy.
31325506	1	60	gly	heavily-glycosylated	150:169	arg1	Bovine submaxillary mucin	Bovine submaxillary mucin				PUBTATOR		mucin	281333		Bovine submaxillary mucin (BSM) is a heavily-glycosylated macromolecular (approximately 4 MDa) protein and is used in various biomaterial applications in light of its high viscosity and biocompatibility, in addition to use as a biochemical substrate or inhibitor as a result of its abundant O-glycans.
29441788	6	6	gly	hypo/nonglycosylated	717:736	arg1	hypo/nonglycosylated rhAFM	hypo/nonglycosylated rhAFM				OGER		rhAFM	P36953		Wild-type and hypo/nonglycosylated rhAFM were purified from cell culture supernatants by immobilized metal ion affinity and size exclusion chromatography.
31169903	6	21	gly	di-glycosylated	797:811	arg1	di-glycosylated TSH	di-glycosylated TSH				OGER		TSH			The di-glycosylated TSH and tri-glycosylated TSH glycoforms were determined and characterized with respect to sialylation and sulfonation.
31169903	6	83	gly	tri-glycosylated	821:836	arg1	tri-glycosylated TSH	tri-glycosylated TSH				OGER		TSH			The di-glycosylated TSH and tri-glycosylated TSH glycoforms were determined and characterized with respect to sialylation and sulfonation.
31169903	6	99	gly	glycoforms	842:851	arg1	tri-glycosylated TSH	TSH				OGER		TSH			The di-glycosylated TSH and tri-glycosylated TSH glycoforms were determined and characterized with respect to sialylation and sulfonation.
29769321	10	13	gly	RpNCRD	1761:1766	arg1	the glycan-binding specificity	RpNCRD			the glycan-binding specificity	Cterm		RpNCRD	6441		The presence of the N-glycan in the CRD increases the glycan-binding specificity of RpNCRD.
31539564	0	30	gly	glycosylation	73:85	arg1	IgG	IgG				Cterm		IgG			Glycan Residues Balance Analysis - GReBA: A novel model for the N-linked glycosylation of IgG produced by CHO cells.
29408166	9	61	gly	core-fucosylated	1681:1696	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		This method could be used in large patient cohorts as core-fucosylated PSA may be a diagnostic biomarker for the differentiation of prostate cancer and other prostatic diseases, such as benign prostatic hyperplasia (BPH).
30302011	2	23	gly	glycosylated	258:269	arg1	Env	Env				PUBTATOR		However, Env	100616444		However, Env is densely glycosylated and thereby substantially protected from neutralisation.
31790908	1	12	gly	glycosylated	134:145	arg1	The ICChI	The ICChI				Cterm		ICChI			The ICChI is a 35-kDa, glycosylated protein isolated from the latex of the weed Ipomoea carnea.
31888963	9	77	part_of	CD16a	1313:1317	arg1	N38	CD16a		N38		PUBTATOR	SpecificSite	CD16a	2214	N38 and N74	N38 and N74 of CD16a both contain highly processed complex-type N-glycans with N-acetyllactosamine repeats and complex-type biantennary N-glycans dominate at N169.
29751008	1	67	gly	glycoforms	254:263	arg1	4 well-defined IgG1-Fc glycoforms	4 well-defined IgG1-Fc glycoforms				OGER		IgG1	P01857		We have used hydrogen exchange-mass spectrometry to characterize local backbone flexibility of 4 well-defined IgG1-Fc glycoforms expressed and purified from Pichia pastoris, 2 of which were prepared using subsequent in vitro enzymatic treatments.
29408166	6	83	gly	core-fucosylated	1317:1332	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		The imprecision of the method over two days ranged from 9.7-23.2% for core-fucosylated PSA and 10.3-18.3% for total PSA depending on the PSA level.
30651366	6	61	gly	N-glycans	1092:1100	arg1	insect sE2	sE2			N-glycans	OGER		sE2	Q10981		Mass spectrometry demonstrated that all 11 predicted N-glycosylation sites were utilized in both HEK293- and Sf9-derived sE2, but that N-glycans in insect sE2 were on average smaller and less complex.
29858715	1	5	gly	glycoprotein	187:198	arg1	Prolactin-inducible protein	Prolactin-inducible protein				PUBTATOR		Prolactin-inducible protein	5304		Prolactin-inducible protein (PIP) is a glycoprotein found in body secretions from exocrine glands like saliva and seminal plasma.
30152909	0	82	gly	B	84:84	arg1	N-glycan moiety	ribonuclease B			N-glycan moiety	Cterm		ribonuclease B			Selective fragmentation of the N-glycan moiety and protein backbone of ribonuclease B on an Orbitrap Fusion Lumos Tribrid mass spectrometer.
31507595	8	85	gly	glycoforms	1353:1362	arg1	CD52-Fc	CD52-Fc				PUBTATOR		CD52	P31358		When glycoforms of CD52-Fc were fractionated by anion exchange MonoQ-GL chromatography, bioactive fractions displayed mainly tetra-antennary, α-2,3 sialylated N-glycan structures and a lower relative abundance of bisecting GlcNAc structures compared to non-bioactive fractions.
29593217	0	25	gly	natively-glycosylated	96:116	arg1	natively-glycosylated HIV-1 envelope	natively-glycosylated HIV-1 envelope				PUBTATOR		HIV-1 envelope	155971		Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope.
30560888	5	14	gly	FA2-IgG2	948:955	arg1	the main agalactosylated glycan	FA2			the main agalactosylated glycan	PUBTATOR		FA2	2187		Using intra-individual normalization of the main agalactosylated glycan (FA2) of IgG1 vs FA2-IgG2, ASS/IIM and controls were distinguished with an area under the curve (AUC) of 79 ± 6%.
30560888	5	62	gly	IgG1	940:943	arg1	the main agalactosylated glycan	IgG1			the main agalactosylated glycan	OGER		IgG1	P01857		Using intra-individual normalization of the main agalactosylated glycan (FA2) of IgG1 vs FA2-IgG2, ASS/IIM and controls were distinguished with an area under the curve (AUC) of 79 ± 6%.
30737276	3	66	gly	MCP	484:486	arg1	the four N-linked glycans	PBCV-1 MCP			the four N-linked glycans	PUBTATOR		PBCV-1 MCP	917865		The structures of the four N-linked glycans from the PBCV-1 MCP consist of nonasaccharides, and similar glycans are not found elsewhere in the three domains of life.
29324282	7	10	gly	IgG1	1409:1412	arg1	the hypergalactosylated and hypersialylated forms	IgG1			the hypergalactosylated and hypersialylated forms	OGER		IgG1	P01857		No significant changes were observed for the hypergalactosylated and hypersialylated forms of IgG1 with regards to binding to FcRn, FcγRIIA and FcγRIIIA, suggesting that neither half-life in circulation nor their ability to induce an immune response are likely to be affected by these modifications of the glycan chains.
29324282	7	77	gly	hypersialylated	1384:1398	arg1	FcγRIIA	FcγRIIA				PUBTATOR		FcγRIIA	2212		No significant changes were observed for the hypergalactosylated and hypersialylated forms of IgG1 with regards to binding to FcRn, FcγRIIA and FcγRIIIA, suggesting that neither half-life in circulation nor their ability to induce an immune response are likely to be affected by these modifications of the glycan chains.
29324282	7	77	gly	hypersialylated	1384:1398	arg1	FcγRIIIA	FcγRIIIA				PUBTATOR		FcγRIIIA	2214		No significant changes were observed for the hypergalactosylated and hypersialylated forms of IgG1 with regards to binding to FcRn, FcγRIIA and FcγRIIIA, suggesting that neither half-life in circulation nor their ability to induce an immune response are likely to be affected by these modifications of the glycan chains.
29324282	7	77	gly	hypersialylated	1384:1398	arg1	IgG1	IgG1				OGER		IgG1	P01857		No significant changes were observed for the hypergalactosylated and hypersialylated forms of IgG1 with regards to binding to FcRn, FcγRIIA and FcγRIIIA, suggesting that neither half-life in circulation nor their ability to induce an immune response are likely to be affected by these modifications of the glycan chains.
31593720	4	21	gly	-Gla-	798:802	arg1	→4)-Glc-(1→, →3,5)-Ara-(1→, →4)-Gla-(1→, →4)-Rha-(1 → and → 2,4)-Rha-(1→	→4)-Gla			→4)-Glc-(1→, →3,5)-Ara-(1→, →4)-Gla-(1→, →4)-Rha-(1 → and → 2,4)-Rha-(1→	OGER		→4)-Gla	P06280		Monosaccharide composition and methylation analysis suggested that glucose, arabinose, galactose and rhamnose constituted side chains with the molar ratio of 1.22:1.79:1.89:4.46 with the glycosidic linkages of →4)-Glc-(1→, →3,5)-Ara-(1→, →4)-Gla-(1→, →4)-Rha-(1 → and → 2,4)-Rha-(1→.
31593720	4	38	gly	-Ara-	785:789	arg1	→4)-Glc-(1→, →3,5)-Ara-(1→, →4)-Gla-(1→, →4)-Rha-(1 → and → 2,4)-Rha-(1→	→3,5)-Ara			→4)-Glc-(1→, →3,5)-Ara-(1→, →4)-Gla-(1→, →4)-Rha-(1 → and → 2,4)-Rha-(1→	OGER		→3,5)-Ara	O95255		Monosaccharide composition and methylation analysis suggested that glucose, arabinose, galactose and rhamnose constituted side chains with the molar ratio of 1.22:1.79:1.89:4.46 with the glycosidic linkages of →4)-Glc-(1→, →3,5)-Ara-(1→, →4)-Gla-(1→, →4)-Rha-(1 → and → 2,4)-Rha-(1→.
30179797	8	57	gly	glycosylated	1252:1263	arg1	BSA	BSA				Cterm		BSA	P02768		The fluorescence spectra of BSA glycosylated by GLP confirmed the formation of covalent bonds between BSA and GLP through the Maillard reaction which was also confirmed by using thermogravimetric (TGA) and Fourier transform infrared (FTIR) analysis.
29725729	2	71	gly	AFP-L3	532:537	arg1	N-glycan	AFP			N-glycan	PUBTATOR		AFP	174		Each glycoprotein may have multiple glycoforms, and cancer-related ones can be only some specific glycoforms which have much higher sensitivity and specificity; for example, AFP glycoform AFP-L3 with N-glycan of 01Y(61F)41Y41M(31M41Y41L41S61M41Y41L41S is of bigger diagnostic value for hepatocellular carcinoma than total AFP (i.e., combination of all glycoforms).
29324282	8	46	gly	deglycosylated	1692:1705	arg1	the deglycosylated form	form of IgG1				OGER		form of IgG1	P01857		In contrast, no measurable binding was observed for the deglycosylated form of IgG1 with either FcγRIIA or FcγRIIIA, although this form of the antibody retained the ability to associate with FcRn.
31877766	0	36	gly	Glycosylation	14:26	arg1	Osteopontin	Osteopontin				PUBTATOR		Osteopontin	6696		The Impact of Glycosylation of Osteopontin on Urinary Stone Formation.
30708016	3	16	gly	ESP	393:395	arg1	total carbohydrate content	ESP			total carbohydrate content	OGER		ESP	Q6UW49		Specific optical rotation, molecular mass and total carbohydrate content of ESP were -36.3°, 43.8 kDa and 97.2%, respectively.
30030954	1	31	gly	glycosylated	143:154	arg1	Lactoferrin	Lactoferrin				OGER		Lactoferrin	P02788		Lactoferrin is a highly glycosylated antimicrobial protein that contains multiple glycan types.
30030954	1	8	gly	contains	183:190	arg1	Lactoferrin AND multiple glycan types	Lactoferrin			multiple glycan types	OGER		Lactoferrin	P02788		Lactoferrin is a highly glycosylated antimicrobial protein that contains multiple glycan types.
30144627	13	45	gly	glycoforms	2106:2115	arg1	the intact hCGα glycoforms	the intact hCGα glycoforms				PUBTATOR		hCGα 	1113		This work demonstrates for the first time the potential of RPLC-HRMS for the identification of the intact hCGα glycoforms.
30353291	6	43	gly	HDX	900:902	arg1	metal-adducted carbohydrates	HDX			metal-adducted carbohydrates	OGER		HDX	Q7Z353		Herein, we differentiate in-ESI HDX of metal-adducted carbohydrates from gas-phase HDX and illustrate that this method analyzes solvated species.
31877766	4	46	gly	glycosylated	550:561	arg1	glycosylated OPN	glycosylated OPN				PUBTATOR		OPN	6696		The urinary full-length-OPN levels were measured using enzyme-linked immunosorbent assay and glycosylated OPN was measured using a lectin array and lectin blotting.
30782654	9	88	gly	glycosylates	1720:1731	arg1	a cell wall-anchored protein	a cell wall-anchored protein				OGER		protein, a	Q86XJ0		Furthermore, this recombinant enzyme, which weakly interacts with GspA in solution, catalyzes phosphotransfer to GspALMM Altogether, the findings support that A. oris LcpA is an archetypal LCP enzyme that glycosylates a cell wall-anchored protein, a process that may be conserved in Actinobacteria, given the conservation of LcpA and GspA in these high-GC-content organisms.IMPORTANCE In Gram-positive bacteria, the conserved LCP family enzymes studied to date are known to attach glycopolymers, including wall teichoic acid, to the cell envelope.
31289257	6	41	gly	glycosylated	1055:1066	arg1	MAP6	MAP6				PUBTATOR		MAP6	17760		In situ dual co-immunofluorescence analysis and immunoblotting confirmed that MAP6 is glycosylated with Gal-(β-1,3)-GalNAc oligosaccharides, which in turn alters the distribution and structure of MAP6 complexes within neurons.
30209313	3	3	gly	glycosylation	570:582	arg1	Env	Env				PUBTATOR		Env	155971		Upon analysis of three HIV strains, we here find that site-specific glycosylation of Env from infectious virus closely matches Envs from corresponding recombinant membrane-bound trimers.
29500371	1	53	gly	IgG-Fc	151:156	arg1	The N-glycan moiety	IgG			The N-glycan moiety	Cterm		IgG			The N-glycan moiety of IgG-Fc has a significant impact on multifaceted properties of antibodies such as in their effector function, structure, and stability.
31558607	0	42	gly	carrying	106:113	arg1	proBDNF AND sulfated LacdiNAc structures	proBDNF			sulfated LacdiNAc structures	PUBTATOR		proBDNF	627		N-Glycosylation is required for secretion of the precursor to brain-derived neurotrophic factor (proBDNF) carrying sulfated LacdiNAc structures.
31558607	0	42	gly	carrying	106:113	arg1	brain-derived neurotrophic factor AND sulfated LacdiNAc structures	brain-derived neurotrophic factor			sulfated LacdiNAc structures	PUBTATOR		brain-derived neurotrophic factor	627		N-Glycosylation is required for secretion of the precursor to brain-derived neurotrophic factor (proBDNF) carrying sulfated LacdiNAc structures.
31423004	3	7	gly	AT	525:526	arg1	core-fucosylated oligosaccharides	AT			core-fucosylated oligosaccharides	Cterm		AT			Generally, Chinese hamster ovary (CHO) cells produce recombinant human AT (rhAT) with core-fucosylated oligosaccharides.
30564965	3	46	gly	attached	375:382	arg2	α2M AND glycans	α2M			glycans	PUBTATOR		2M	2		In this study, glycans attached to α2M were analysed in a human population of different ages by lectin-based protein microarray.
31362986	9	65	gly	IgA	1708:1710	arg1	N-glycans	IgA			N-glycans	PUBTATOR		IgA	973		In conclusion, N-glycans of human IgA do not affect its structure and integrity but its thermal stability, and FcαRI N-glycans significantly modulate binding affinity to IgA.
30714583	5	11	gly	IgG	609:611	arg1	15 glycan forms	IgG			15 glycan forms	Cterm		IgG			Here, we identified 15 glycan forms of serum IgG from RA and OA using MALDI-TOF MS. We found that IgG galactosylation represented a suitable candidate for differentiating RA from healthy controls (AUC > 0.9).
30948514	7	54	gly	O-glycan	1364:1371	arg1	Ser22			Ser22	Ser22		AminoAcid			Ser22	Finally, the analysis of bovine OPSR by MS identified an O-glycan on Ser22, a residue that is semi-conserved (Ser or Thr) among vertebrate OPSR and OPSG.
29580922	9	25	gly	haptoglobin	1464:1474	arg1	Sialylated glycans	haptoglobin			Sialylated glycans	PUBTATOR		haptoglobin	3240		Sialylated glycans of haptoglobin are a potential biomarker of several diseases, such as hepatocellular carcinoma, liver cirrhosis, and IgA-nephritis.
30612270	0	6	gly	Ceruloplasmin	160:172	arg1	new glycan compositions	Ceruloplasmin			new glycan compositions	PUBTATOR		Ceruloplasmin	1356		Quantitation of Glycopeptides by ESI/MS - size of the peptide part strongly affects the relative proportions and allows discovery of new glycan compositions of Ceruloplasmin.
31888819	4	62	gly	-D-Galp-	661:668	arg1	→6)-D-Galp-(1→, D-Glcp-(1→, →3,6)-D-Manp-(1→, →4)-D-Glcp-(1→ and →6)-D-Glcp-	Galp			→6)-D-Galp-(1→, D-Glcp-(1→, →3,6)-D-Manp-(1→, →4)-D-Glcp-(1→ and →6)-D-Glcp-	OGER		Galp	Q9UBC7		A combination of monosaccharide composition, FT-IR, GC-MS and NMR analysis indicated that CBP70-1-1 was composed of →6)-D-Galp-(1→, D-Glcp-(1→, →3,6)-D-Manp-(1→, →4)-D-Glcp-(1→ and →6)-D-Glcp-(1→ with relative molecular weights of 12,724 Da, and CBP70-1-2 was composed of →4)-D-Glcp-(1→, D-Glcp-(1→, →3,6)-D-Manp-(1→, →6)-D-Galp-(1→, →4,6)-D-Glcp-(1→ and →3)-L-Araf-(1→ with relative molecular weights of 3611 Da.
29343613	5	73	gly	site	892:895	arg1	gp120	gp120			site	PUBTATOR		gp120	3700		MVN is a monovalent lectin with a single glycan-binding site in gp120, is structurally similar to CVN and exhibits no toxicity or mitogenicity, both of which are liabilities with CVN.
30427198	3	28	gly	endo-α-mannosidase	597:614	arg1	glucosyl carbasugar α-aziridines	endo-α-mannosidase			glucosyl carbasugar α-aziridines	PUBTATOR		endo-α-mannosidase	79694		Using NMR and X-ray crystallography, it is shown that glucosyl carbasugar α-aziridines can act as reasonably potent endo-α-mannosidase inhibitors, likely by virtue of their shape mimicry and the interactions of the aziridine nitrogen with the conserved catalytic acid/base of the enzyme active site.
31548313	9	60	gly	glycans	1483:1489	arg1	IgG	IgG			glycans	Cterm		IgG			These structural features were consistent with the activity of Endo-CoM on fucose-containing glycans on rituximab (IgG) and its preference for a sialobiantennary substrate.
30640124	0	52	gly	antigen	72:78	arg1	the glycan structure	prostate-specific antigen			the glycan structure	PUBTATOR		prostate-specific antigen	354		Focusing aptamer selection on the glycan structure of prostate-specific antigen: Toward more specific detection of prostate cancer.
30612271	10	24	gly	released	1120:1127	arg1	VC1 AND N-glycans	VC1			N-glycans	Cterm		VC1			N-glycans released from VC1 ranged from Man9GlcNAc2- to Man15GlcNAc2- with major Man10GlcNAc2- and Man11GlcNAc2- species for p36 and p34, respectively.
29420040	1	9	gly	glycoprotein	195:206	arg1	the trimeric HIV-1 envelope glycoprotein spike	the trimeric HIV-1 envelope glycoprotein spike				PUBTATOR		HIV-1 envelope glycoprotein	155971		Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (Env) are tools that can guide the design of recombinant Env proteins intended to engage the predicted human germline precursors of bNAbs (gl-bNAbs).
29420040	1	9	gly	glycoprotein	195:206	arg1	Env	Env				PUBTATOR		Env	155971		Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (Env) are tools that can guide the design of recombinant Env proteins intended to engage the predicted human germline precursors of bNAbs (gl-bNAbs).
31888963	9	84	gly	contain	1324:1330	arg1	CD16a AND highly processed complex-type N-glycans	CD16a			highly processed complex-type N-glycans	PUBTATOR		CD16a	2214		N38 and N74 of CD16a both contain highly processed complex-type N-glycans with N-acetyllactosamine repeats and complex-type biantennary N-glycans dominate at N169.
31373757	0	65	gly	Glycosylation	36:48	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		OGT Controls the Expression and the Glycosylation of E-cadherin, and Affects Glycosphingolipid Structures in Human Colon Cell Lines.
29595997	3	43	gly	glycosylated	506:517	arg1	Env	Env				PUBTATOR		Because Env	100616444		Because Env is heavily glycosylated compared to host glycoproteins, the glycans have become targets for the antibody response.
30898876	5	6	gly	presence	1178:1185	arg1	protein 1	low-density lipoprotein receptor-related protein 1			presence	PUBTATOR		low-density lipoprotein receptor-related protein 1	4035		Our results further revealed that LDN presence on low-density lipoprotein receptor-related protein 1 and nicastrin depends on B3GALNT2, indicating the occurrence of type-I LDN in vivo in mammalian cells.
30898876	5	6	gly	presence	1178:1185	arg1	nicastrin	nicastrin			presence	OGER		nicastrin	Q92542		Our results further revealed that LDN presence on low-density lipoprotein receptor-related protein 1 and nicastrin depends on B3GALNT2, indicating the occurrence of type-I LDN in vivo in mammalian cells.
29992770	9	56	gly	N-glycopeptides	1236:1250	arg1	IgG1	IgG1				OGER		IgG4	P01861		N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls.
29992770	9	56	gly	N-glycopeptides	1236:1250	arg1	transferrin	transferrin				PUBTATOR		transferrin	7018		N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls.
29992770	9	56	gly	N-glycopeptides	1236:1250	arg1	IgG4	haptoglobin				PUBTATOR		haptoglobin	3240		N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls.
31611356	1	45	gly	sites	277:281	arg1	HIV-1 gp120	HIV-1 gp120			sites	PUBTATOR		HIV-1 gp120	3700		Griffithsin (Grft) is an antiviral lectin that has been shown to potently inhibit HIV-1 by binding high-mannose N-linked glycosylation sites on HIV-1 gp120.
30291933	5	11	gly	SPP	792:794	arg1	monosaccharide composition	SPP			monosaccharide composition	OGER		SPP	Q8TCT9		Sulfated modification resulted in some changes in chemical component, molecular weight and monosaccharide composition of SPP.
29888865	0	46	gly	N-glycosylation	23:37	arg1	human plasma-derived factor VIII	human plasma-derived factor VIII				PUBTATOR		factor VIII	2157		In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications.
30348313	6	39	gly	Deglycosylated	768:781	arg1	Deglycosylated R-TBN1	Deglycosylated R-TBN1				PUBTATOR		TBN1	100037736		Deglycosylated R-TBN1 and mutant N94D/N112D were virtually inactive.
29674057	5	20	gly	glycoproteins	828:840	arg1	interferon-beta-1a	interferon-beta-1a				OGER		interferon-beta	P01574		We have explored the capacity of hydrophilic liquid chromatography-mass spectrometry (HILIC-MS) for assessing glycosylation patterns of intact pharmaceutical proteins by analyzing the complex glycoproteins interferon-beta-1a (rhIFN-β - 1a) and recombinant human erythropoietin (rhEPO).
29674057	5	20	gly	glycoproteins	828:840	arg1	recombinant human erythropoietin	recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		We have explored the capacity of hydrophilic liquid chromatography-mass spectrometry (HILIC-MS) for assessing glycosylation patterns of intact pharmaceutical proteins by analyzing the complex glycoproteins interferon-beta-1a (rhIFN-β - 1a) and recombinant human erythropoietin (rhEPO).
29740059	0	26	gly	sialylation	100:110	arg1	recombinant EPO	recombinant EPO				PUBTATOR		EPO	P01588		Inhibition of poly-LacNAc biosynthesis with release of CMP-Neu5Ac feedback inhibition increases the sialylation of recombinant EPO produced in CHO cells.
29740059	0	44	gly	EPO	127:129	arg1	the sialylation	EPO			the sialylation	PUBTATOR		EPO	P01588		Inhibition of poly-LacNAc biosynthesis with release of CMP-Neu5Ac feedback inhibition increases the sialylation of recombinant EPO produced in CHO cells.
31084922	11	57	gly	O-glycosylation	1810:1824	arg1	HSPN	HSPN				OGER		HSPN	O75398		The IgA1 O-glycosylation profile of HSPN was very similar to that of IgAN.
31040271	5	26	gly	glycoforms	904:913	arg1	α-galactosidase A	α-galactosidase A				PUBTATOR		-galactosidase A	11605		We demonstrate distinct circulation time and organ distribution of selected glycoforms of α-galactosidase A in a Fabry disease mouse model, and find that an α2-3 sialylated glycoform designed to eliminate uptake by the mannose 6-phosphate and mannose receptors exhibits improved circulation time and targeting to hard-to-reach organs such as heart.
31892825	6	40	gly	N-glycoform	1510:1520	arg1	native miraculin	native miraculin				PUBTATOR		miraculin	101255468		These results indicate that the N-glycoform of native miraculin from miracle fruit and recombinant miraculin expressed in tomato plants are almost identical to each other with similar ratios and that, therefore, plant-specific N-glycans are essential for showing the full taste-modifying activity of miraculin.
30553311	9	81	gly	contained	1123:1131	arg1	PHP AND total carbohydrates	PHP			total carbohydrates	OGER		PHP	Q9DAK9		Analysis of chemical characterization showed that PHP contained 75.36 ± 1.48% of total carbohydrates, 24.63 ± 1.69% of uronic acid residue and no proteins with monosaccharides such as rhamnose, arabinose, xylose, mannose, glucose, and galactose in a molar ratio of 10.25:9.38:1:12.45:9.9:11.55.
30892132	5	37	gly	PD-1	1007:1010	arg1	The glycan modifications	PD-1			The glycan modifications	PUBTATOR		PD-1	5133		The glycan modifications of PD-1 could be observed in three potential N-linked glycosylation sites, while no substantial influences were detected to the binding of toripalimab.
31851597	3	48	gly	E-cadherin	667:676	arg1	the O-mannosylation	E-cadherin			the O-mannosylation	PUBTATOR		E-cadherin	999		Here, biochemical, cell biological, and organismal analysis was used to determine that TMTC3 supports the O-mannosylation of E-cadherin, cellular adhesion, and embryonic gastrulation.
31851597	3	74	gly	O-mannosylation	648:662	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		Here, biochemical, cell biological, and organismal analysis was used to determine that TMTC3 supports the O-mannosylation of E-cadherin, cellular adhesion, and embryonic gastrulation.
30813247	0	58	gly	Contains	53:60	arg1	Recombinant Glycoprotein E AND Glycan-Peptide Motifs	Recombinant Glycoprotein E			Glycan-Peptide Motifs	Cterm		Recombinant Glycoprotein E			Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures.
30564965	7	24	gly	α2M	1260:1262	arg1	the glycan moieties	2M			the glycan moieties	PUBTATOR		2M	2		Thus, the binding of IGFBP-2 to α2M seems to be related to structural changes in the glycan moieties of α2M, whereas binding of Zn ions, most likely, is not.
30640124	4	28	gly	PSA	710:712	arg1	the glycan moiety	PSA			the glycan moiety	PUBTATOR		PSA	P07288		Using this strategy, we identified one aptamer (PSA-1) that binds the glycan moiety of PSA with reasonable affinity (a dissociation constant of 177 ± 65 nM).
30389790	4	0	gly	Δgls1-S	890:896	arg1	the most abundantly formed glycans	gls1			the most abundantly formed glycans	OGER		gls1	O94925		The sick strain displayed only G3M9 as an ER protein-linked oligosaccharide, whereas the healthier strain had both G3M9 and Man9GlcNAc2 The lipid-linked oligosaccharide patterns of the two strains revealed that the most abundantly formed glycans were G3M9 in Δgls1-S and Glc2Man9GlcNAc2 in Δgls1-H, suggesting reduced Alg10p glucosyltransferase activity in the Δgls1-H strain.
30389790	4	96	gly	Δgls1-H	921:927	arg1	the most abundantly formed glycans	gls1			the most abundantly formed glycans	OGER		gls1	O94925		The sick strain displayed only G3M9 as an ER protein-linked oligosaccharide, whereas the healthier strain had both G3M9 and Man9GlcNAc2 The lipid-linked oligosaccharide patterns of the two strains revealed that the most abundantly formed glycans were G3M9 in Δgls1-S and Glc2Man9GlcNAc2 in Δgls1-H, suggesting reduced Alg10p glucosyltransferase activity in the Δgls1-H strain.
31190665	6	65	gly	glycosylated	1375:1386	arg1	glycosylated GST	glycosylated GST				OGER		GST			This is only the second reported and characterized glycosylated GST and our study highlights its potential role in host-parasite interactions and use in the study of human onchocerciasis.
30403372	1	51	gly	glycoprotein	254:265	arg1	Env	Env				PUBTATOR		Env	155971		VRC01 broadly neutralizing antibodies (bnAbs) target the CD4-binding site (CD4BS) of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env).
31325506	0	47	gly	mucin	33:37	arg1	N-glycans	mucin			N-glycans	PUBTATOR		mucin	281333		N-glycans of bovine submaxillary mucin contain core-fucosylated and sulfated glycans but not sialylated glycans.
29632412	3	19	gly	GlcNAc	962:967	arg1	murine IgGs	IgG			GlcNAc	Cterm		IgG	668542		By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function.
29632412	3	35	gly	glycosylation	1079:1091	arg1	IgG function	IgG function				PUBTATOR		IgG	668542		By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function.
29535710	1	9	gly	glycoprotein	100:111	arg1	Immunoglobulin G	Immunoglobulin G				Cterm		Immunoglobulin G			Immunoglobulin G (IgG), a glycoprotein secreted by plasma B-cells, plays a major role in the human adaptive immune response and are associated with a wide range of diseases.
29441788	5	36	gly	nonglycosylated	583:597	arg1	Fully nonglycosylated rhAFM	Fully nonglycosylated rhAFM				OGER		rhAFM	P36953		Fully nonglycosylated rhAFM was obtained by transfection of point-mutated cDNA to delete all N-glycosylation sites of afamin.
29441788	5	43	gly	N-glycosylation	670:684	arg1	afamin	afamin				PUBTATOR		afamin	173		Fully nonglycosylated rhAFM was obtained by transfection of point-mutated cDNA to delete all N-glycosylation sites of afamin.
29441788	1	37	gly	glycoprotein	96:107	arg1	Afamin	Afamin				PUBTATOR		Afamin	173		Afamin is an 87 kDa glycoprotein with five predicted N-glycosylation sites.
29769533	1	58	gly	glycoprotein	153:164	arg1	the HIV envelope glycoprotein	the HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	100616444		Furin cleavage of the HIV envelope glycoprotein is an essential step for cell entry that enables formation of well-folded, native-like glycosylated trimers, releases constraints on the fusion peptide, and limits enzymatic processing of the N-glycan shield.
30842877	3	48	gly	glycosylation	390:402	arg1	IgA1	IgA1				PUBTATOR		IgA1	P01876		In this study, the glycosylation of IgA1 was evaluated using serum samples from patients with breast cancer (BCa) and the utility of IgA1 glycosylation as a biomarker was assessed.
30016589	4	59	part_of	IgG	927:929	arg1	the IgG Tyr296 residue	IgG		the IgG Tyr296 residue		PUBTATOR	AminoAcid	IgG	668542	Tyr296 residue	Fc fucosylation restricted the manifold of conformations sampled by displacing the CD16a Asn162-glycan that impinges upon the linkage between the α-mannose(1-6)β-mannose residues and promoted contacts with the IgG Tyr296 residue.
31260704	3	21	gly	N-glycopeptides	516:530	arg1	IgG1	IgG1				OGER		IgG1	P01857		In this work, we present a high-throughput matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) method based on a microarray technology to monitor N-glycopeptides of IgG1 produced in a perfusion cell culture.
29726048	9	34	gly	CETP	1501:1504	arg1	glycans	CETP			glycans	PUBTATOR		CETP	P11597		Thus, glycans are an integral part of CETP, further studies on the CETP inhibition and treatment of CVD should fully consider the effect of glycans.
29408166	8	91	gly	core-fucosylated	1553:1568	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		To our knowledge, this is the first MS-based method for quantification of core-fucosylated PSA in the low ng/ml concentration range in human serum.
31130941	7	53	part_of	pIgA	1545:1548	arg1	Asn459	pIgA		Asn459		OGER	AminoAcid	pIgA	P37287	Asn459	The hydrolysis of pIgA was subsequently utilized for the specific glycan characterization of the released pIgA Fc-tail (Asn459).
31892825	3	26	gly	miraculin	600:608	arg1	N-glycan	miraculin			N-glycan	PUBTATOR		miraculin	101255468		For practical use therefore, the differences between N-glycan of recombinant miraculin compared to that of native miraculin should be minimized.
31558607	6	11	gly	glycosylated	1132:1143	arg1	secreted proBDNF	secreted proBDNF				PUBTATOR		proBDNF	627		Using an optimized LC-MS/MS workflow, we demonstrate that secreted proBDNF is fully glycosylated and carries rare N-glycans terminated by GalNAcβ1-4GlcNAcβ1-R (LacdiNAc) extensively modified by terminal sulfation.
31558607	6	59	gly	carries	1149:1155	arg1	secreted proBDNF AND rare N-glycans	secreted proBDNF			rare N-glycans	PUBTATOR		proBDNF	627		Using an optimized LC-MS/MS workflow, we demonstrate that secreted proBDNF is fully glycosylated and carries rare N-glycans terminated by GalNAcβ1-4GlcNAcβ1-R (LacdiNAc) extensively modified by terminal sulfation.
31325506	7	38	gly	glycopeptides	1520:1532	arg1	BSM	BSM				Cterm		BSM	281333		The N-glycosylation sites were identified from the analysis of glycopeptides from BSM.
31244828	12	66	gly	glycoforms	1843:1852	arg1	MOG	MOG				PUBTATOR		MOG	4340		The most abundant glycoforms of MOG expressed in HEK cells are diantennary, contain a core fucose, an antennary fucose, and are decorated with α2,6 linked Neu5Ac, while details of the glycoforms of MOG in myelin remain to be identified.
31244828	12	75	gly	glycoforms	1677:1686	arg1	MOG	MOG				PUBTATOR		MOG	4340		The most abundant glycoforms of MOG expressed in HEK cells are diantennary, contain a core fucose, an antennary fucose, and are decorated with α2,6 linked Neu5Ac, while details of the glycoforms of MOG in myelin remain to be identified.
31998308	2	3	gly	afucosylated	274:285	arg1	afucosylated IgG glycovariants	afucosylated IgG glycovariants				PUBTATOR		IgG glycovariants	668542		Thus, afucosylated IgG glycovariants have enhanced cytotoxic activity, whereas IgG glycovariants rich in terminal sialic acid residues can trigger anti-inflammatory effects.
30086262	12	39	gly	glycosylation	1983:1995	arg1	MUC16	MUC16				OGER		MUC16	Q8WXI7		Human PDAC cells with knockout of C1GALT1 had aberrant glycosylation of MUC16 compared with control cells and increased expression of genes that regulate tumorigenesis and metastasis.
32110292	7	35	gly	N-glycosylation	1393:1407	arg1	IgG	IgG				Cterm		IgG			Combined with high-energy collisional dissociation for the fragmentation of glycans, fine mapping of the N-glycosylation profile of IgG is achieved.
30213862	0	43	gly	CD16a	0:4	arg1	oligomannose-type N-glycans	CD16a			oligomannose-type N-glycans	PUBTATOR		CD16a	2214		CD16a with oligomannose-type N-glycans is the only "low affinity" Fc γ receptor that binds the IgG crystallizable fragment with high affinity in vitro.
31412214	7	21	gly	glycosylation	1337:1349	arg1	non-GPI-anchored cytosolic CD59	non-GPI-anchored cytosolic CD59				OGER		CD59	P13987		Our results suggest that CD59 is retrotranslocated from the endoplasmic reticulum to the cytosol, a process mediated by recognition of trimmed N-linked oligosaccharides, supported by the partial glycosylation of non-GPI-anchored cytosolic CD59 as well as the failure of N-linked glycosylation site mutant CD59 to reach the cytosol or rescue GSIS.
30770394	7	87	gly	included	951:958	arg1	VWF	VWF				PUBTATOR		VWF	7450		This variation included terminal sialylation and ABO(H) blood group expression on VWF.
29409697	5	9	gly	glycosylated	1247:1258	arg1	hGnTII	hGnTII				PUBTATOR		hGnTII	4247		The enzyme was found to be N-glycosylated by the enzymatic cleavage of glycans, while hGnTII expressed in insect cells had not been reported to be glycosylated.
30427586	3	53	gly	glycoproteins	509:521	arg1	fibrinogen	fibrinogen				PUBTATOR		fibrinogen	2244		Using a set of four representative and biopharmaceutically relevant glycoproteins (IgG, fibrinogen, lactotransferrin, and ribonuclease B), the benefits and limitations of the developed workflow are highlighted and a state-of-the-art blueprint for conducting high-quality in-depth N- and O-glycoproteomic analyses is provided.
30427586	3	53	gly	glycoproteins	509:521	arg1	IgG	IgG				Cterm		IgG			Using a set of four representative and biopharmaceutically relevant glycoproteins (IgG, fibrinogen, lactotransferrin, and ribonuclease B), the benefits and limitations of the developed workflow are highlighted and a state-of-the-art blueprint for conducting high-quality in-depth N- and O-glycoproteomic analyses is provided.
30427586	3	53	gly	glycoproteins	509:521	arg1	lactotransferrin	lactotransferrin				PUBTATOR		lactotransferrin	4057		Using a set of four representative and biopharmaceutically relevant glycoproteins (IgG, fibrinogen, lactotransferrin, and ribonuclease B), the benefits and limitations of the developed workflow are highlighted and a state-of-the-art blueprint for conducting high-quality in-depth N- and O-glycoproteomic analyses is provided.
29924315	0	75	gly	Siglec-8	45:52	arg1	Sialylated keratan sulfate proteoglycans	Siglec-8			Sialylated keratan sulfate proteoglycans	PUBTATOR		Siglec-8	27181		Sialylated keratan sulfate proteoglycans are Siglec-8 ligands in human airways.
30910671	3	9	gly	PNP-60	501:506	arg1	the polysaccharide contents	PNP			the polysaccharide contents	OGER		PNP	P00491		The results indicate that the polysaccharide contents of PNP-40, PNP-60, and PNP-80 are 45.12%, 78.04%, and 72.22%, respectively, while the β-glucan, protein, and uronic acid contents are 20.20%, 12.20%, and 10.15%, respectively; 11.24%, 14.53%, and 26.94%; and 5.99%, 7.73%, and 3.78%.
30910671	3	12	gly	PNP-40	493:498	arg1	the polysaccharide contents	PNP			the polysaccharide contents	OGER		PNP	P00491		The results indicate that the polysaccharide contents of PNP-40, PNP-60, and PNP-80 are 45.12%, 78.04%, and 72.22%, respectively, while the β-glucan, protein, and uronic acid contents are 20.20%, 12.20%, and 10.15%, respectively; 11.24%, 14.53%, and 26.94%; and 5.99%, 7.73%, and 3.78%.
30910671	3	15	gly	PNP-80	513:518	arg1	the polysaccharide contents	PNP			the polysaccharide contents	OGER		PNP	P00491		The results indicate that the polysaccharide contents of PNP-40, PNP-60, and PNP-80 are 45.12%, 78.04%, and 72.22%, respectively, while the β-glucan, protein, and uronic acid contents are 20.20%, 12.20%, and 10.15%, respectively; 11.24%, 14.53%, and 26.94%; and 5.99%, 7.73%, and 3.78%.
30564965	5	23	gly	glycosylation	730:742	arg1	α2M	α2M				PUBTATOR		2M	2		The increased glycosylation of α2M was accompanied by reduced binding of Zn ions and insulin-like growth factor-binding protein 2 (IGFBP-2).
30674035	5	25	gly	released	664:671	arg2	CSF purified IgG AND N-Glycans	CSF purified IgG			N-Glycans	Cterm		IgG			N-Glycans were released from CSF purified IgG with peptide N-glycosidase F, labeled with 2-aminobenzamide and analyzed by NP-HPLC chromatography in combination with exoglycosidase digestion and MALDI-TOF mass spectrometry.
31877766	3	42	gly	glycosylated	257:268	arg1	urinary glycosylated OPN	urinary glycosylated OPN				PUBTATOR		OPN	6696		We retrospectively measured urinary glycosylated OPN normalized by urinary full-length-OPN levels in 110 urolithiasis patients and 157 healthy volunteers and 21 patients were prospectively longitudinal follow-up during stone treatment.
31246420	4	10	gly	O-glycosylated	661:674	arg1	the heavily O-glycosylated protein lubricin	the heavily O-glycosylated protein lubricin				PUBTATOR		lubricin	10216		Here we take a multiple reaction monitoring (MRM) approach to differentiate and relatively quantify all detectable glycans, including isomers, on the heavily O-glycosylated protein lubricin.
29624401	2	10	gly	CDs	389:391	arg1	alkyl grafted polysaccharide chains	CDs			alkyl grafted polysaccharide chains	OGER		CDs	Q92903		Recently, new types of inclusions of α CDs with alkyl grafted polysaccharide chains (pullulan, chitosan, dextran, amylopectin, chondroitin sulfate...) have been prepared which are autoassembled into micro- and nanoplatelets.
29740059	3	4	gly	sialylation	445:455	arg1	recombinant human erythropoietin	recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis.
29740059	3	4	gly	sialylation	445:455	arg1	rhEPO	rhEPO				OGER		rhEPO	P11678		Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis.
29740059	3	47	gly	erythropoietin	478:491	arg1	the sialylation	erythropoietin			the sialylation	PUBTATOR		erythropoietin	2056		Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis.
31501225	7	56	gly	glycopeptides	1162:1174	arg1	IgA2	IgA2				OGER		IgA2	P01877		In contrast, the two glycopeptides of IgA2 fell back down in HBV-related HCC patients.
29367749	3	37	gly	RebA	669:672	arg1	the Glc(β1→C-19 residue	RebA			the Glc(β1→C-19 residue	Cterm		RebA			Structural analysis of the products by MALDI-TOF mass spectrometry, methylation analysis and NMR spectroscopy showed that both enzymes exclusively glucosylate the Glc(β1→C-19 residue of RebA, with the initial formation of an (α1→6) linkage.
31521285	3	21	gly	contains	370:377	arg1	HBE-III AND 15 different monosaccharides	HBE-III			15 different monosaccharides	OGER		HBE	P02100		HBE-III is a 10 kDa acidic polysaccharide, which contains 15 different monosaccharides and 23 glycosyl linkages, indicating it is a highly branched complex polysaccharide.
30209313	1	22	gly	glycoprotein	176:187	arg1	Env	Env				PUBTATOR		Env	155971		As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective bnAbs in humans.
30209313	1	22	gly	glycoprotein	176:187	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective bnAbs in humans.
30209313	2	18	gly	glycosylation	433:445	arg1	recombinant Env	recombinant Env				PUBTATOR		Env a	155971		Because HIV Env is densely glycosylated with 75-90 N-glycans per trimer, most bnAbs use or accommodate them in their binding epitope, making the glycosylation of recombinant Env a key aspect of HIV vaccine design.
30209313	2	42	gly	glycosylated	315:326	arg1	HIV Env	HIV Env				PUBTATOR		Env	155971		Because HIV Env is densely glycosylated with 75-90 N-glycans per trimer, most bnAbs use or accommodate them in their binding epitope, making the glycosylation of recombinant Env a key aspect of HIV vaccine design.
29346724	5	71	gly	N-glycosylated	596:609	arg1	EXTL3ΔN	EXTL3ΔN				PUBTATOR		EXTL3ΔN	2137		In this work, human lumenal N-glycosylated EXTL3 (EXTL3ΔN) was cloned, expressed in human embryonic kidney cells, and purified.
29346724	5	71	gly	N-glycosylated	596:609	arg1	human lumenal N-glycosylated EXTL3	human lumenal N-glycosylated EXTL3				PUBTATOR		N-glycosylated EXTL3	2137		In this work, human lumenal N-glycosylated EXTL3 (EXTL3ΔN) was cloned, expressed in human embryonic kidney cells, and purified.
31122132	4	88	gly	aglycosylated	1031:1043	arg1	an aglycosylated polymeric IgA	an aglycosylated polymeric IgA				PUBTATOR		IgA	P11912		We further explore two strategies to overcome the rapid serum clearance of polymeric IgA: removal of all N-linked glycosylation sites creating an aglycosylated polymeric IgA and engineering in FcRn binding with the generation of a polymeric IgG-IgA Fc fusion.
30392563	1	7	gly	glycoproteins	87:99	arg1	Mucin glycoproteins	Mucin glycoproteins				PUBTATOR		Mucin glycoproteins	100508689		Mucin glycoproteins on the ocular surface are rich in O-glycans and have important roles in the protection from physical, chemical and microbial impact.
31548313	11	8	gly	has	1734:1736	arg1	a known core fucose-specific ENGase AND a similar fucose-binding pocket	a known core fucose-specific ENGase			a similar fucose-binding pocket	OGER		ENGase	Q8NFI3		In particular, Endo-F3, a known core fucose-specific ENGase, has a similar fucose-binding pocket, but the surrounding residues are not shared with Endo-CoM.
29405331	3	78	gly	glycoprotein	428:439	arg1	A1AT	A1AT				PUBTATOR		A1AT	5265		The serum glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated glycosites was used in this study.
30003921	7	74	gly	glycoproteins	914:926	arg1	thyroglobulin	thyroglobulin				OGER		thyroglobulin	P01266		Surface plasmon resonance revealed differential binding of BinA with glycoproteins (fetuin, asialofetuin and thyroglobulin) and affinity for simple sugars, l-fucose and l-arabinose.
29463753	0	73	gly	glycosylation	47:59	arg1	gp120	gp120				OGER		gp120	Q14624		Signal peptide of HIV envelope protein impacts glycosylation and antigenicity of gp120.
31100702	4	6	gly	glycoprotein	609:620	arg1	a PNGase F glycoprotein digest	a PNGase F glycoprotein digest				OGER		PNGase F glycoprotein	Q96IV0		In this work we compared two methods aiming at recovering N-glycans in a high yield and at high purity from a PNGase F glycoprotein digest of bovine lactoferrin.
29898396	1	0	gly	glycoprotein	185:196	arg1	Env	Env				PUBTATOR		Env	100616444		Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typically take years to develop.
29898396	1	0	gly	glycoprotein	185:196	arg1	the HIV envelope glycoprotein	the HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	100616444		Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typically take years to develop.
29615747	3	36	gly	glycoproteins	448:460	arg1	GPs	GPs				OGER		GPs			Here, we report that the structural features of ebolavirus envelope glycoproteins (GPs) and one of their counter receptors, macrophage galactose-type calcium-type lectin (MGL/CD301), play crucial roles in determining viral infectivity.
31169903	2	52	gly	TSH	318:320	arg1	sialylation	TSH			sialylation	OGER		TSH			The degree of sialylation of serum TSH was reported to be very low in normal third-trimester fetuses compared with normal adults.
31169903	2	56	gly	sialylation	297:307	arg1	serum TSH	serum TSH				OGER		TSH			The degree of sialylation of serum TSH was reported to be very low in normal third-trimester fetuses compared with normal adults.
29642453	6	21	gly	glycosylation	1072:1084	arg1	NA	NA				PUBTATOR		NA	4758		After the 2009 pandemic, recent isolates accrued glycosylation at canonical sites in HA, reflecting gradual seasonal adaptation, and a novel glycosylation in NA as an independent signature for adaptation among humans.
31881468	1	1	gly	glycoprotein	176:187	arg1	MOG	MOG				PUBTATOR		MOG	4340		Myelin Oligodendrocyte glycoprotein (MOG) is found to play an important role in providing structural integrity to myelin sheath at the same time it acts as an auto-antigen which might lead to Multiple Sclerosis (MS).
31881468	1	1	gly	glycoprotein	176:187	arg1	Myelin Oligodendrocyte glycoprotein	Myelin Oligodendrocyte glycoprotein				PUBTATOR		Myelin Oligodendrocyte glycoprotein	4340		Myelin Oligodendrocyte glycoprotein (MOG) is found to play an important role in providing structural integrity to myelin sheath at the same time it acts as an auto-antigen which might lead to Multiple Sclerosis (MS).
31531180	1	45	gly	Tea	231:233	arg1	polysaccharides	Mist Tea			polysaccharides	OGER		Mist Tea	Q7Z7G1		The study was designed to investigate the chemical composition and antioxidant activities of polysaccharides from Yingshan Cloud Mist Tea.
30612271	0	38	gly	N-glycosylation	29:43	arg1	the human receptor	the human receptor				PUBTATOR		receptor for advanced glycation end products	177		Insights into the effects of N-glycosylation on the characteristics of the VC1 domain of the human receptor for advanced glycation end products (RAGE) secreted by Pichia pastoris.
31468229	0	55	gly	glycosylated	14:25	arg1	glycosylated human prolactin	glycosylated human prolactin				PUBTATOR		prolactin	5617		Expression of glycosylated human prolactin in HEK293 cells and related N-glycan composition analysis.
29579062	5	18	gly	Env	952:954	arg1	the oligosaccharide components	Env			the oligosaccharide components	PUBTATOR		Env	155971		Considering that lectins exclusively recognize the oligosaccharide components of virus Env, these data suggest that glycan heterogeneity among HIV-1 isolates may explain this differential sensitivity.